Official Protocol Title:
NCT number:                [STUDY_ID_REMOVED]
Document Date:            09-Jun-[ADDRESS_1200299]: MK-2060  1
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD) .
Protocol Title: A Study to Evaluate Safety and Tolerability of Co-administration of MK -
2060 and Clopi[INVESTIGATOR_861132]- Stage Renal Disease on Hemodialysis
Protocol Number: 008-01
Compound Number: MK-2060
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_1200300], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
EudraCT 2021- 005333- 17
IND 142, 237
Approval Date: [ADDRESS_1200301]: MK-2060  2
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08BRCT
PRODUCT: MK-2060  3
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200302] the Sponsor’s entity name [CONTACT_148231], and to correct typographical errors.
MK-2060- 008-[ADDRESS_1200303]: MK-2060  4
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: [01]
Overall Rationale for the Amendments:
The original protocol is being amended to add standard text on photography of rash, to reflect the Sponsor ’s entity name [CONTACT_26405], and to correct typographical errors .These changes should not impose any undue safety risks to the participant nor have any 
impact on the PK/PD of MK -2060.
Summary of Changes Table:
Section # and Name [CONTACT_861195] s ite in the US will be participating 
in the study
Title Page
Section 10.1.[ADDRESS_1200304] for Clinical TrialsSponsor entity name [CONTACT_259712] & Dohme Corp. underwent an entity 
name [CONTACT_19520] & Dohme 
LLC, Rahway, NJ, [LOCATION_003]. This conversion resulted only 
in an entity name [CONTACT_26406].
Section 3 Hypotheses, 
Objectives, and EndpointsRemoved “ -008” from the tertiary 
objective “ To investigate the relationship 
between the genetic polymorphism s of 
CYP2C19 and the pharmacokinetics of 
MK-2060.”Correction of typographical error
08BRCT
PRODUCT: MK-2060  5
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Section # and Name [CONTACT_9353] 8.1.9 
Discontinuation and 
Withdrawal
Section 8.5 Adverse Events, 
Serious Adverse Events, and 
Other Reportable Safety 
Events
Section 10.3.1 Definition of 
AE
Section 10.3.5 Reporting of 
AEs, SAEs, and Other 
Reportable Safety Events to 
the SponsorChanged references of sections 8.4 , 8.4.1, 
8.4.3, and 8.4.6 to 8.5 , 8.5.1, 8.5.3, and 
8.5.6,respectivelyCorrection of typographical erro rs
Section [IP_ADDRESS] Resting V ital 
SignsRevised sentence to read “ The same 
method must be used for all measurements 
for each individual participant and should 
be the same for all participants at a given 
site”Clarified that temperature measurements should be 
taken from the same locati on for all participants at a 
given site.
Section 8.3.[ADDRESS_1200305]: MK-2060  6
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Section # and Name [CONTACT_9353] 1.[ADDRESS_1200306]: MK-2060  7
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 17
1.3 Schedule of Activities........................................................................................... 18
2 INTRODUCTION .......................................................................................................... 22
2.1 Study Rationale ....................................................................................................22
2.2 Background .......................................................................................................... 22
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 22
2.2.2 Ongoing Clinical Studies ............................................................................. 22
2.2.3 Information on Other Study -related Therapy .............................................. 24
2.3 Benefit/Risk Assessment ...................................................................................... 25
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 25
4 STUDY DESIGN ............................................................................................................ 27
4.1 Overall Design ......................................................................................................27
4.2 Scientific Rationale for Study Design ................................................................ .27
4.2.1 Rationale for Endpoints ............................................................................... 28
[IP_ADDRESS] Safety Endpoints ................................................................................ 28
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 29
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 30
[IP_ADDRESS] Planned Exploratory Bioma rker Research......................................... 30
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 30
[IP_ADDRESS] Future Biomedical Research .............................................................. 30
4.3 Justification for Dose ........................................................................................... 31
4.3.1 Rationale for Dose Interval and Study Design ............................................ 31
4.4 Beginning and End -of-Study Definition ............................................................ 32
4.4.1 Clinical Criteria for Early Study Termination ............................................. 32
5 STUDY POPULATION ................................................................................................ 32
5.1 Inclusion Criteria ................................................................................................ .33
5.2 Exclusion Criteria ................................................................................................ 35
5.3 Lifestyle Considerations ...................................................................................... 38
5.3.1 Meals and Dietary Restrictions ....................................................................38
[IP_ADDRESS] Diet Restrictions................................................................................. [ADDRESS_1200307]: MK-2060  8
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 38
[IP_ADDRESS] Alcohol Restr ictions........................................................................... 38
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 39
5.3.3 Activity Restrictions .................................................................................... 39
5.4 Screen Failures .....................................................................................................39
5.5 Participant Replacement Strategy ......................................................................39
6 STUDY INTERVENTION ............................................................................................ 39
6.1 Study Intervention(s) Administered ...................................................................39
6.2 Preparation/Handling/Storage/Accountability ................................................. 41
6.2.1 Dose Preparation .......................................................................................... 41
6.2.2 Handling, Storage, and Accountability ........................................................ 41
6.3 Measures to Minimize Bias: Randomization and Bl inding .............................. 42
6.3.1 Intervention Assignment.............................................................................. 42
6.3.2 Stratification ................................................................................................ .42
6.3.3 Blinding ........................................................................................................42
6.4 Study Intervention Compliance .......................................................................... 42
6.5 Concomitant Therapy .......................................................................................... 42
6.5.1 Rescue Medications and Supportive Care ................................................... 45
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_1200308] to Follow -up................................................................................................ .49
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 49
8.1 Administrative and General Procedures ........................................................... 50
8.1.1 Informed Consent ......................................................................................... 50
[IP_ADDRESS] General Informed Consent ................................................................ .50
[IP_ADDRESS] Consent and C ollection of Specimens for Future Biomedical 
Research ............................................................................................. 50
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_1200309]: MK-2060  9
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
8.1.5 Prior and Concomitant Medications Review ............................................... 51
[IP_ADDRESS] Prior Medications ............................................................................... 51
[IP_ADDRESS] Concomitant Medications ..................................................................51
8.1.6 Assignment of Screening Number ............................................................... 51
8.1.7 Assignment of Treatment/Randomization Number .....................................52
8.1.8 Study Intervention Administration .............................................................. 52
[IP_ADDRESS] Timing of Dose Administration ......................................................... 52
8.1.9 Discontinuation and Withdrawal ................................................................ .52
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 52
8.1.10 Participant Blinding/Unb linding ..................................................................53
8.1.11 Domiciling ...................................................................................................53
8.1.12 Calibration of Equipment ............................................................................. 53
8.2 Efficacy/Immunogenicity Assessments .............................................................. 53
8.3 Safety Assessments ............................................................................................... 54
8.3.1 Physical Examinations ................................................................................. 54
[IP_ADDRESS] Body Weight and Height ...................................................................54
[IP_ADDRESS] Body Mass Index (BMI) ....................................................................54
8.3.2 Vital Signs ....................................................................................................54
[IP_ADDRESS] Resting Vital Signs ............................................................................ 55
[IP_ADDRESS] Orthostatic Vital Signs .......................................................................[ADDRESS_1200310]- dose ............................... 57
8.4.1 Systemic Infusion Reaction Assessment ..................................................... 58
8.4.2 Local Infusion Reaction Assessment ........................................................... 58
8.5 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 59
8.5.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 59
8.5.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......61
8.5.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...61
8.5.4 Regulatory Reporting Requirements for SAE ............................................. 61
8.5.5 Pregnancy and Exposure During Breastfeeding .......................................... 61
8.5.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_1200311]: MK-2060  10
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
8.6 Treatment of Overdose ........................................................................................ 62
8.7 Pharmacokinetics ................................................................................................ .63
8.7.1 Blood Collection for Plasma MK -2060 and Clopi[INVESTIGATOR_7745] ............................ 63
8.8 Pharmacodynamics .............................................................................................. 63
8.9 Biomarkers ........................................................................................................... 63
8.9.1 Planned Genetic Analysis Sample Collection.............................................. 63
8.9.2 Blood Collection for PT, aPTT, FXI Activity ............................................. 63
8.9.3 Blood for Plasma ADA ................................................................................ 64
8.10 Future Biomedical Research Sample Collection ............................................... 64
8.11 Visit Re quirements............................................................................................... 64
8.11.1 Screening and Run -in Period .......................................................................64
8.11.2 Treatment Period .......................................................................................... 64
8.11.3 Poststudy ......................................................................................................65
8.11.4 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study ................................................................................ 65
8.11.5 Critical Procedures Based on Study Objectives: Timing of Procedure .......65
8.11.6 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 67
9 STATISTICAL ANALYSIS PLAN ............................................................................. 68
9.1 Statistical Analysis Plan Summary .....................................................................68
9.2 Responsibility for Analyses ................................................................................. 68
9.3 Hypotheses/Estimation ........................................................................................ 68
9.4 Analysis Endpoints ............................................................................................... 69
9.5 Analysis Populations ............................................................................................ 69
9.6 Statistical Methods ............................................................................................... 70
9.7 Interim Analyses ..................................................................................................71
9.8 Multiplicity ........................................................................................................... 71
9.9 Sample Size and Power Calculations ................................................................ .71
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................72
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........72
10.1.1 Code of Conduc t for Clinical Trials ............................................................. 72
10.1.2 Financial Disclosure ..................................................................................... 74
10.1.3 Data Protection ............................................................................................. 75
[IP_ADDRESS] Confidentiality of Data ......................................................................75
[IP_ADDRESS] Conf identiality of Participant Records ............................................... 75
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ [ADDRESS_1200312]: MK-2060  11
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
10.1.5 Publication Policy ........................................................................................ 76
10.1.6 Compliance with Study Registration and Results Posting Requirements ...76
10.1.7 Compliance w ith Law, Audit, and Debarment ............................................ 76
10.1.8 Data Quality Assurance ............................................................................... 77
10.1.9 Source Documents ....................................................................................... 78
10.1.10 Study and Site Closure ................................................................................. 78
10.2 Appendix 2: Clinical Laboratory Tests.............................................................. 79
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 80
10.3.1 Definition of AE .......................................................................................... 80
10.3.2 Definition of SAE ........................................................................................ 81
10.3.3 Additional Events Reported ......................................................................... 82
10.3.4 Recording AE and SAE ............................................................................... 82
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................86
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up.............................................................................................................. 87
10.5 Appendix 5: Contraceptive Guidance ................................................................ 88
10.5.1 Definitions ....................................................................................................88
10.5.2 Contraception Requirements ........................................................................89
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 90
10.7 Appendix 7: Country -specific Requirements .................................................... 95
10.8 Appendix 8: Blood Volume Table ......................................................................96
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values .......97
10.10 Appendix 10: Abbr eviations ............................................................................... [ADDRESS_1200313]: MK-2060  12
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200314] OF TABLES
Table 1 Study Schema ................................................................................................... 17
Table 2 Preliminary Part 2 Plasma Pharmacokinetic Parameters [Geometric Mean 
(%GCV)] of MK- 2060 Following Multiple 60-minute IV infusion Doses 
of 25 mg QW ...................................................................................................23
Table 3 Study Interventions .......................................................................................... 40
Table 4 Local Infusion Reaction Assessment ............................................................... 58
Table 5 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 60
Table 6 Pharmacokinetic (Blood), Pharmacodynamic and Biomarker Collection 
Windows .......................................................................................................... [ADDRESS_1200315]: MK-2060  13
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200316]: MK-2060  14
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Study to Evaluate Safety and Tolerability of Co -administration of MK -
2060 and Clopi[INVESTIGATOR_861133] -Stage Renal Disease on Hemodialysis
Short Title: MK-2060 and Clopi[INVESTIGATOR_861134]-administration Safety and Tolerability Study
Acronym: NA
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
This study is to be conducted in adult participants with End -Stage Renal Disease on 
Hemodialysis. 
Objectives Endpoints
Primary
•Objective: To assess the safety and 
tolerability following multiple doses of 
concomitant treatment of MK -2060 and 
clopi[INVESTIGATOR_7745]•Bleeding related AEs, AEs and 
discontinuations due to AEs
Secondary
•Objective: To evaluate plasma 
pharmacokinetics of MK -2060 following 
multiple doses of concomitant treatment 
of MK -2060 and clopi[INVESTIGATOR_7745] •MK-2060 plasma AUC0- 168, Cmax, 
C168, Tmax, terminal t1/2, CL, Vz
•Objective: To evaluate the time required 
to achieve hemostasis following 
completion of dialysis in ESRD patients
following concomitant treatment of MK -
2060 and clopi[INVESTIGATOR_7745]
•Hypothesis: Mean time -to-hemostasis for 
MK-2060 treatm ent is less than 20 
minutes•Time to hemostasis
08BRCT
PRODUCT: MK-2060  15
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Overall Desig n:
Study Phase Phase 1
Primary Purpose Treatment
Indication Graft thrombosis
Population Patient: adult participants with end -stage renal disease on 
hemodialysis
Study Type Interventional
Intervention Model Single Group
This is a multi- sitestudy.
Type of Control None
Study Blinding Unblinded Open -label
Blinding Roles No Blinding
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 17months from the time the first 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant’s last study- related contact .
Number of Participant s:
Up to 12participants will be allocated .
08BRCT
PRODUCT: MK-2060  16
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Intervention Groups and Du ration :
Intervention 
Group sInter -
vention 
Group 
Name [CONTACT_210648]-
tration Regimen Use
NA MK-2060 25mgWeek 1: 3
doses 
Week 2: 1 
doseIntravenousWeek 1: 3
doses
Week 2: 1 
doseExperimental
Total 
Number of 
Intervention 
Groups/
ArmsThere will be [ADDRESS_1200317]. After a screening phase of approximately 4 weeks
and run -in period of approximately 2 weeks , each participant will receive 
assigned intervention for approximately 2weeks. After the end -of-
treatment each participant will be followed for approximately 9 6days.
Study Governance Committees:
Executive Ove rsight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations is in Appendix 11.
08BRCT
PRODUCT: MK-2060  17
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200318] based on newly available safety, tolerability, pharmacokinetic 
and/or pharmacodynamic data observed in this study as well as other MK -[ADDRESS_1200319]: MK-2060  18
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
1.3 Schedule of Activities
Study Period:Scr
een
-ing Run-inaInterventionPost-
study
Intervention
Notes
Scheduled Day
Day -14
Day -7
Day -3
Day 1
Day2
Day 3
Day 5
Day 8Day 9
Day 10Day 12
Day 15Day 21
Day 29
Day 35Day 49
Day 67
Day 104Administrative Procedures
Informed Consent X Sec. [IP_ADDRESS]
Informed Consent for 
FBRX Sec. 8.1.1. [ADDRESS_1200320] X Sec. 8.1.3
Inclusion/Exclusion 
CriteriaX X X XSec. 5.1, 5.2, and 8.1.2
Review of IC/ECat Screening and during Run -in period ; 
only specific criteria w ill be reviewed predose prior to 
treatment alloca tionon Day 1
Participant Bracelet X Sec. 4.3.1
Medical History X Sec 8.1.4
Prior/Concomitant 
Medication ReviewX X X X X X X X X X X X X X X X X X X Sec. 6.5 & 8.1.[ADDRESS_1200321] Clopi[INVESTIGATOR_473521] X X X X X X X X X X X X
Domiciling XXXXX Sec. 8.1.11
On site Hemodialysis
(HD)b X X X X X X X X
Safety Procedures
Full physical 
examinationX X X X X X XSec. 8.3.[ADDRESS_1200322]: MK-2060  19
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Study Period:Scr
een
-ing Run-inaInterventionPost-
study
Intervention
Notes
Scheduled Day
Day -14
Day -7
Day -3
Day 1
Day2
Day 3
Day 5
Day 8Day 9
Day 10Day 12
Day 15Day 21
Day 29
Day 35Day 49
Day 67
Day 104Local Infusion Reaction 
AssessmentX X X X X X Sec. 8.4.2
Assessment of Time to 
HemostasisX X X X X X XSec. 8.3.4. 
Performed immediately at the end of HD
Height XSec. 8.3.1
Height may be measured during Screening or Run -in
period .
Weight X XSec. 8.3.1 , weight for BMI to be taken during Screening or 
Run-in period.
Additional weight measurements can be taken per site 
SOP.
Resting Semi -
Recumbent Vital Signs 
(blood pressure, heart 
rate, respi[INVESTIGATOR_697], 
body temperature)X X X X X X X X X X X X X X X XSec. 8.3.2 .1
To be d one at predose on Days 1, 3, 5 and 8
Orthostatic VS X X X X X X X X X XSec. 8.3.2 .2
To be d one at predose on Days 1, 3, 5 and 8 .
To be done before start of dialysis on Days -3 and 15.
12-lead ECG X X X X X X X X XSec. 8.3.3
To be do ne at predose on Days 1, 3, 5 and 8
Serum FSH -
(WO NCBP only)X
Serum or Urine 
Pregnancy test ( WOCBP 
only)X X X
HIV, hepatitis B and C 
screen X
Drug Screen and 
Alcohol Breath TestX XAppendix [ADDRESS_1200323] is mandatory at 
Screen ingand predose; any additional DS and alcohol 
breath tests are conducted per site SOP
Blood or saliva DS may be used for anuric participants
08BRCT
PRODUCT: MK-2060  20
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Study Period:Scr
een
-ing Run-inaInterventionPost-
study
Intervention
Notes
Scheduled Day
Day -14
Day -7
Day -3
Day 1
Day2
Day 3
Day 5
Day 8Day 9
Day 10Day 12
Day 15Day 21
Day 29
Day 35Day 49
Day 67
Day 104Hematology X X X X X X X X X X X XSec. 8.3.5
Appendix 2
To be done predose on Days 1, 3 and 8
aPTT/PT at Local Lab X X X X X X X X X X X X XSec. 8.3.5
Appendix 2
Days 1 , 3, 5 & 8: predose, 1h and12h.
ChemistrycX X X X X X X X X X X XSec. 8.3.5
Appendix 2
To be done at predose on Days 1, 3 and 8
Hemoccult TestdX X XX X X X X Sec. 8.3.5, 8.11.5
AE/SAE review X XXXXXXXXXXXXXXXXX X Sec 8. 5, Appendix 3
Pharmacokinetics
Blood for Plasma 
MK-2060 Assaye, f X X X X X X X X X X X X X X XSec. 8.7
Days 1 & 8 : predose, 1h, 12h. 
Days 3 &5: predose, 1h.
See footnote s e, f
Blood for Clopi[INVESTIGATOR_861135],f X X X X X X X XSec. 8.7
See footnote e, f.
Pharmacodynamics
Blood for PT/aPTT/ FXI 
Activity by [CONTACT_861178] X X X X X X X X X X X X X X XSec. 8.8, Days 1 & 8: predose and 1h (within 15 min of end 
of infusion ).
Days 3 &5: predose
Biomarkers
Blood for Plasma ADAfX X X X XSec. 8. 9.3
Day 1: predose
Blood (DNA) fo r 
Planned Genetic 
Analysis X See section 8.[ADDRESS_1200324]: MK-2060  21
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Study Period:Scr
een
-ing Run-inaInterventionPost-
study
Intervention
Notes
Scheduled Day
Day -14
Day -7
Day -3
Day 1
Day2
Day 3
Day 5
Day 8Day 9
Day 10Day 12
Day 15Day 21
Day 29
Day 35Day 49
Day 67
Day 104ADA=antidrug antibody; AE=adverse event; DNA=deoxyribonucleic acid; ECG=electrocardiogram; FBR=future biomedical research; FSH=follicle stimulating hormone; 
hCG=human chorionic gonadotropin; HD= hemodialysis; ID=identification; SAE=serious adverse event; S OP=standard operating procedure; VS=vital signs; WOCBP=women 
of childbearing potential ; WONCBP= women of non -childbearing potential .
aRun-in period (Day -14 to Day -3)should be approximately 2 weeks before the initial dose of MK -2060 . 
bOn site Hemodialysis:  Pre -dose blood sample collections will be collected prior to HD initiation .
cParticipants should fastfor at least [ADDRESS_1200325] available sample if not within this time window.
eAll pre-dose PK should be taken prior to initiation of dialysis on that day.
fLeftover main study plasma will be stored for future biomedical research if the participant (or their legally acceptable repr esentative) provides documented informed consent 
for FBR.
08BRCT
PRODUCT: MK-2060  22
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
2 INTRODUCTION
2.1 Study Rationale
MK-2060 is an anti -factor XI monoclonal antibody, being developed for prevention of 
thrombotic complications in end-stage renal disease ( ESRD ). Many ESRD patients take 
P2Y12 inhibitors as a concomitant antiplatelet therapy. The purpose of this study is to 
conduct a preliminary evaluation of the safety and tolerability of MK-[ADDRESS_1200326].  Based on preclinica l and human genetic data, as well as emerging 
clinical data using an anti -sense oligo (ASO) approach [Buller, H. R., et al 2015] [Bethune, 
C., et al 2017] ,FXI inhibition is predicted to confer a clinically relevant antithrombotic effect 
with a reduced risk of bleeding complications and hence an expanded therapeutic index 
compared to inhibition of more downstream clotting factors such as FXa and thrombin.  
Therefore, FXI/FXIa inhibition is a promising therapeutic approach for the prevention of 
thromboembolic complications.
2.2.2 Ongoing Clinical Studies
MK-2060- 004:
MK-2060- 004 is a double -blind, randomized, placebo- controlled, multiple site, sequential 
panel, sing le and multiple dose trial of MK -2060 in adult participants ( men and women of 
non-child bearing potential) with ESRD on HD .As of 14-Dec-2021, [ADDRESS_1200327] 
been no AEs suggestive of hypersensitivity.  Refer to IB Edition 5for a detailed o verview of 
Part 1 of 
the study, and available preliminary PK, PD, and safety results for Part 1.
Updated Pharmacokinetic Data from MK -2060- 004 Part 2 since IB Ed 5:
Analysis of preliminary PK from the single dose portion of MK- 2060- 004 (Part 1) suggested 
that a multiple dose regimen (25 mg dose on Day 1, 3, and 5, followed by 3 once -weekly 
maintenance doses of 25 mg) would result in rapid achievement of the Cmax at steady state. 
The projected Cmax steady state levels were comparable to what was observed for a single 
[ADDRESS_1200328]: MK-2060  23
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
The IB was revised to include observed multiple dose PK parameters from Part 2 of MK-
2060- 004. PK parameters from 18 subjects in Part 2 are presented in [ Table 2]. The observed 
PK concentration profiles from the Part 2 multiple -dose participant s are consistent with the 
projected PK concentrations using the Part 1 single dose data, suggesting that the PK of MK -
2060 is not time dependent.
Preliminary analysis detected no ADA positive samples over 150 days following a single 
dose of MK- 2060 in Part 1 of MK -2060 PN004 in ERSD participants. Also, in Part 2 
following multiple doses of MK- 2060, no ADA positive samples were found over 111 days 
after initiation of dosing.
Table 2 Preliminary Part 2 Plasma Pharmacokinetic Parameters [Geometric Mean 
(%GCV)] of MK- 2060 Following Multiple 60 -minute IV infusion Doses of 25 mg QW
Cmax_day1
(nM)Cmax_day22
(nM)Tmax_day1a
(hr)Tmax_day 22a
(hr)Cmax 
Ratio 
(Day 22 
Day 1)Post-wk1 C predose (nM) Post-wk1 C eoi(nM)
Day 
8Day 
15Day 
22Day 
29Day 
8Day 
15Day 
22
32.4 
(37.7)93.4 
(31.7)1.00
(1.00 –
48.00)b1.00
(1.00 –
24.00)b2.68 
(33.5)47.1
(28.1)44.7 
(32.0)44.8 
(36.0)44.6 
(32.1)91.4 
(24.1)96.8 
(32.2)93.5 
(33.3)
a Median (Min -Max)
bOn Day 1 one patient had Cmax at 48 hrs and on Day 22 five patients and one patient had Cmax at 12 and 24 hrs 
respectively.
Updated Pharmacodynamic Activity Data from MK -2060- 004 Part 2 since IB Ed 5:
In patients with ESRD on HD, following multiple doses of 25 mg of MK -2060, aPTT 
prolongation was observed with maximum mean fold change of approximately 2.95. The 
maximum aPTT prolongation occurred at ~ [ADDRESS_1200329] dose on Day 22 (end of infusion at 
the last dose). The multiple 25 mg doses inhibited FXI to a maximum level of approximately 
2% of normal activity (based upon normal range of FXI activity standardized in the assay). 
The maximum inhibition of FXI activity was observed at 1 hour on Day 22.
Updated Safety Data from MK -2060- 004 Part 2 since IB Ed 5:
As of 14-Dec-2021, [ADDRESS_1200330] dose due to not meeting Inclusion Criterion #1 
(the participant is not being dialyzed via AVF or AVG).
Multiple IV doses of [ADDRESS_1200331]: MK-2060  24
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
discontinued the study drug due to AEs. One participant discontinued study drug due to the 
drug-related SAE lower gastrointestinal hemorrhage (additional information provided below)
and another participant discontinued from the study drug due to a nonstudy drug related AE 
(COVID- 19 infection). and did not receive the last dose on Day 22.
A total of 7 participants in Part 2 reported total 8 non- serious AEs (7 mild AEs, 1 moderate 
AE diarrhea) and 4 SAEs. Two AEs reported in one participant (mild nausea and mild 
sneezing) were considered as study drug related by [CONTACT_093]. All other non -serious 
AEs were considered as not study drug related by [CONTACT_093]. 
A total of 4 participants in Part 2 reported total 4 SAEs, in which 1 SAE was considered as 
drug-related by [CONTACT_1755] 3 SAEs were considered as not study drug related by [CONTACT_1275]. One participant reported a drug -related SAE of lower gastrointestinal 
hemorrhage after Day 5 dosing. This patient experienced bright red blood per rectum and 
was hospi[INVESTIGATOR_861136] a precaution.  During the hospi[INVESTIGATOR_861137], no blood 
transfusion or other blood products were required, and the bleeding resolved with 
conservative therapy.  A lower gastrointestinal endoscopy revealed the source of the blee d 
was from internal hemorrhoids.  One participant reported a nonstudy drug related SAE of 
pneumonia (hospi[INVESTIGATOR_057]) approximately [ADDRESS_1200332] dose. One participant reported 
a nonstudy drug related SAE of myocardial infarction (hospi[INVESTIGATOR_861138]) approximately [ADDRESS_1200333] dose. All 4 participants recovered f rom the SAEs.
Across all treatments for Part 1 and Part 2 of the study, apart from mechanism -based aPTT 
increases, there were no clinically significant changes from baseline for ECGs, safety labs, 
and no changes in hematology labs suggestive of bleeding aside from the lower 
gastrointestinal haemorrhage summarized above . Similarly, an exploratory assessment of 
time to vascular access site hemostasis after removal of the hemodialysis catheters remained 
unchanged from baseline.
MK-2060- 007:
MK-2060- [ADDRESS_1200334] receiving hemodialysis via an 
AVG. This phase 2 study is designed to evaluate the efficacy and safety of MK- 2060 20 mg 
QW and MK 2060 6 mg QW (with three loading doses in Week 1) . As of 14-Dec-2021, 32 
participants enrolled in MK -2060- 007 with a maximum exposure of 78 days. MK-2060- 007 
is ongoing and safety data are blinded and preliminary. 
2.2.3 Information on Other Study -related Therapy
Clopi[INVESTIGATOR_861139]. Clopi[INVESTIGATOR_861140] (ADP) to its platelet receptor (P2Y12) and the subsequent 
ADP -mediated activation of the glycoprotein GPI[INVESTIGATOR_97086]/IIIa complex, thereby [CONTACT_861179]. Biotransformation of clopi[INVESTIGATOR_861141] 
08BRCT
PRODUCT: MK-2060  25
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200335] day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, 
the average inhibition level observed with a dose of 75 mg clopi[INVESTIGATOR_861142] 
40% and 60%. 
Platelet aggregation and blee ding time gradually return to baseline values after treatment is 
discontinued, generally in about 5 days. After repeated 75 -mg oral doses of clopi[INVESTIGATOR_7745] 
(base), plasma concentrations of the parent compound, which has no platelet inhibiting 
effect, are very low and are generally below the quantification limit beyond [ADDRESS_1200336] on the bioavailability of clopi[INVESTIGATOR_861143]. Clopi[INVESTIGATOR_861144] 75 mg clopi[INVESTIGATOR_7745], with peak plasma levels of 
the main circulating metabolite occurring approximately 1 hour afte r dosing. 
The use of clopi[INVESTIGATOR_861145]. Thrombotic thrombocytopenic 
purpura has been reported rarely following use of clopi[INVESTIGATOR_7745], s ometimes after a short 
exposure (<2 weeks). Clopi[INVESTIGATOR_861146], surgery, or 
other pathological conditions (particularly gastrointestinal and intraocular).
2.3 Benefit/Risk Asse ssment
Participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safety and 
properties of an investigational medicine. 
Additional details regarding speci fic benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
[ADDRESS_1200337]: MK-2060  26
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Objectives Endpoints
Primary
•Objective: To assess the safety and 
tolerability following multiple doses of 
concomitant treatment of MK -2060 and 
clopi[INVESTIGATOR_7745]•Bleeding related AEs, AEs and 
discontinuations due to AEs
Secondary
•Objective: To evaluate plasma 
pharmacokinetics of MK -2060 following 
multiple doses of concomitant treatment 
of MK -2060 and clopi[INVESTIGATOR_7745] •MK-2060 plasma AUC0- 168, Cmax, 
C168, Tmax, terminal t1/2, CL, Vz
•Objective: To evaluate the time required 
to achieve hemostasis following 
completion of dialysis in ESRD patients
following concomitant treatment of MK -
2060 and clopi[INVESTIGATOR_7745]
•Hypothesis: Mean time -to-hemostasis for 
MK-2060 treatm ent is less than 20 
minutes•Time to hemostasis
Tertiary/Exploratory
•Objective: To explore the effect of 
concomitant treatment of MK -2060 and 
clopi[INVESTIGATOR_861147].•aPTT fold change from baseline
•Objective: To explore the effect of 
concomitant treatment of MK -2060 and 
clopi[INVESTIGATOR_861148].•Prothrombin time fold change from 
baseline
•Objective: To evaluate plasma 
pharmacokinetics of clopi[INVESTIGATOR_7745] 
(clopi[INVESTIGATOR_861149]) following 
multiple doses of concomitant treatment 
of MK -2060 a nd clopi[INVESTIGATOR_7745]•Clopi[INVESTIGATOR_7745] (clopi[INVESTIGATOR_861150])plasma concentration
•Objective: To explore the development of 
ADAs measured in blood samples 
following multiple doses of concomitant 
treatment of MK -2060 and clopi[INVESTIGATOR_7745]•ADA
08BRCT
PRODUCT: MK-2060  27
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Objectives Endpoints
•Objective: To investigate the relationship 
between the genetic polymorphisms of 
CYP2C19 and the pharmacokinetics of 
MK-2060. Variation in CYP2C19 may be 
analyzed for association with any 
laboratory or clinical data collected in this 
study•Germline genetic variation in 
CYP2C19 and association to clinical 
data collected in this study
4 S TUDY DESIGN
4.1 Overall Design
This is an open label, multi -site, multiple dose trial of MK -2060 in adult participants (men 
and women) with ESRD o n HD to be conducted in conformance with Good Clinical Practice.  
The study will evaluate the safety and tolerability of MK -[ADDRESS_1200338] participan tsreceiving clopi[INVESTIGATOR_861151] . After an approximately 14-dayrun-in period to enable measurement of baseline time 
to hemostasis and AE monitoring, e ach participant will receive a loading dose of 25mg IV 
MK-2060 for a total of 3 doses in week 1 and a single dose of25mg IV MK -2060 in week 2.
Participants will be closely monitored for safety and tolerability, including safety labs, local 
lab aPTT and PT results, physical exam to check bleeding related AEs, vital signs (VS) and 
12-lead ECG, as well as local infusion site reactions and systemic reactions to MK-[ADDRESS_1200339]: MK-2060  28
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
(PN001) and single/multiple dose assessment in ESRD/HD patients. Preliminary safety data 
from PN [ADDRESS_1200340]/HD patients taking clopi[INVESTIGATOR_861152], since such patients 
require antiplatelet/P2Y12 inhibitor treatment for variety of comorbidities occurring in 
conjunction with their renal disease and hemodialysis treatment. Pertinent to this study 
design, a study of c lopi[INVESTIGATOR_51153] l in chronic HD patients showed no impact of clopi[INVESTIGATOR_861153]-to-hemostasis following removal of dialysis catheters [Kaufman, J. S., et al 2000] . 
Furthermore, a recent publication suggested that use of clopid ogrel in patients with severe 
FXI deficiency/hemophilia type C does not add to the bleeding risk in that particular 
population [Perek, S., et al 2017] . Other FXI inhibitors in clinical development have
demonstra ted low risk of bleeding with FXI inhibition . Taken together, these data support 
conducting this study with MK -[ADDRESS_1200341]/HD patients receiving clopi[INVESTIGATOR_861154] .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Safety Endpoints
Based onthedata from PN001 (healthy subject study) and PN004 ,it is expected that
multiple dose IVadministration ofMK- [ADDRESS_1200342] on HD. However, thesafety andtolerability following multiple doses of concomitant 
treatment of MK-2060 and clopi[INVESTIGATOR_861155]. Physical examinations, VS,ECGs, laboratory safety tests (serum
chemistry and hematology), aPTT, PT,andAEs related tobleeding willbeassessed
throughout thetreatment period. AEs, including local infusion sitereactions andsystemic
reactions toMK-2060 infusion, willbeassessed throughout thetreatment period.
Bleeding related AEs will include any sign or symptom of bleeding, even if not requi ring 
intervention by a medical/healthcare professional, as well as clinically -relevant non major 
bleeding or major bleeding.
Aswith allbiologic medications, MK-[ADDRESS_1200343] assevere
headache, nausea, vomiting, back pain, fever, hypotension andmultiorgan failure. Therisk
ofany ofthese infusion reactions toMK-2060 isconsidered lowgiven itsprofile in
preclinical safety studies. There were no infusion reactions , no acute hypersensitivity 
reactions, and no cytokine release reactions observed so far in any MK -2060 clinical studies
(see Investigator’s Brochure for more information on the Phase [ADDRESS_1200344]: MK-2060  29
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
with MK -2060) . Participants willbemonitored closely during theinfusion with scheduled
VSandphysical examinations asindicated in the Schedule of Activities .In
addition tomonitoring foracute reactions toMK-2060, theinfusion sitewillbeassessed
forsigns ofreactogenicity, including pain, tenderness, erythema andswelling by[CONTACT_464],
particularly during thefirst week after infusion. AEs andSAEs willbecollected through
Day 104.
Time to adequate hemostasis after decannulation of vascular access
A secondary objective of this study is to explore the effect of MK -[ADDRESS_1200345] patients on clopi[INVESTIGATOR_60469].  In the dialysis unit after the completion 
of hemodialysis the dialysis catheters are removed from the dialysis access site (i.e., AV 
fistula or AV graft).  Upon decannulation ,pressure is held until adequate hemostasis has 
been obtained for both the arte rial and venous sites. In this study the process is standardized 
such that change in time to hemostasis from baseline (i.e., average of values obtained from 
the run- in period ) can be assessed (see the operations manual for details).
On three dialysis visit s prior to dosing ,time to adequate hemostasis for both the arterial and 
venous sites will be assessed to establish a baseline (mean of three run-in period 
assessments). Should time to hemostasis be different for arterial and venous sites, the longer 
of the two should be recorded. This endpoint will then be assessed at the end of the dialysis 
sessions after each dosing days as specified in the SoA . Change from baseline will be 
calculated. 
Anti -drug antibodies (ADAs) toMK-2060
Thepresence andtiterofADAs willbemeasured using validated assays. ADAs candevelop
tobiologics likeMK-2060. ADAs may beclinically inconsequential ormay change thePK
and/or drug efficacy. Moreover, ADAs may lead tosafety events, such asacute ordelayed
hypersensitivity reactions. Thus, thetiter ofADAs will becorrelated with PKandsafety
events. Ifneeded, positive ADAs willbefurther evaluated todetermine whether they areable
toneutralize MK-[ADDRESS_1200346] theability
toneutralize theaction ofMK-2060.
[IP_ADDRESS] Pharmacokinetic Endpoints
Plasma PK of MK -2060
The evaluation of MK -2060 PK will include determination of non-compartmental PK 
parameters including AUC0 -168, Cmax, C168, Tmax,terminal t1/2, CL and Vz .
08BRCT
PRODUCT: MK-2060  30
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
[IP_ADDRESS] Pharmacodynamic Endpoints
aPTT and FXI activity (performed by[CONTACT_221452])
Inorder toassess PD, thisstudy will include anassessment ofaPTT prolongation levels
(relative tobaseline), and FXI activity levels, with assays being performed ataCentral
Laboratory. ForPK/PD modeling, aPTT andFXI activity levels will berelated toplasma
exposure. The time points forPDdata collection arebased ontheprojected PKprofile of
MK-2060. Estimation ofthe aPTT effects of MK-2060 following multiple well-tolerated
dosesisanexploratory objective ofthisstudy.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_1200347] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug ADME; mechanism of action of the drug; disease etiology; and/or 
molecular subtype of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a sample will be collected for DNA analysis from consenting participants.
DNA samples may be used for researc h related to the study intervention(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes, the analysis of genetic 
markers throughout the genome, or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
In addition to studying variation across the human genome, CYP2C19 genotypi[INVESTIGATOR_861156].
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on specimens for which consent was pr ovided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR .
Such resear ch is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of coll ecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure that participants receive the cor rect dose of 
the correct drug/vaccine at the cor rect time. The details of FBR r esearch are presented in
Appendix 6.
08BRCT
PRODUCT: MK-2060  31
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
4.3 Justification for Dose
The dosing regimen for MK -2060 (2 5mg IV on days 1, 3, 5 of week 1 as loading phase , and 
25mg IV once in week 2) is thesame as the first two weeks dosing of the high dose arm in 
the ongoing Ph2 study (P N007) and first two weeks of dosing of part [ADDRESS_1200348] patients. This dose is projected to result in ~90% of participants with an aPTT of 
>1.5Xbaseline at Cmin during steady state (C168) .The observed median Cmax is 93.[ADDRESS_1200349] patients receiving hemodialysis (MK- 2060- 004, incomplete data of Part 2)which 
achieved similar exposures as the projected steady state exposures of 25 mg in P N007 
(median Cmax of 77 nM and median Cmin of 42 nM) .As this is a Phase 1 assessment of 
MK-2060 inhumans, and the PK , pharmacodynamic and safety profiles of the compound are 
still being evaluated, modifications to the dose or dosing regimen may be required to achieve 
the scientific goals of the study objectives and/or to ensure appropriate safety monitoring of 
the study participants. Details of allowed modifications are provided i n Section 8.11.6.
4.3.[ADDRESS_1200350]/HD population is the target patient population for MK -2060, and a proportion of 
ESRD patients are taking antiplatelet therapy, such as clopi[INVESTIGATOR_7745]. Dosing of MK-[ADDRESS_1200351] and FXI inhibition/aPTT prolongation is 
maximized (but not exceeding exposures observed in previous trials in ESRD/HD patients). 
With the slow clearance of MK -2060, there will be prolonged pharmacology during washout, 
during which time safety and bleeding -related AEs will continue to be monitored. 
Each participant will be dosed and observed until discharge (~ 24hours post -dose) for 
safety/tolerability.  24hours is sufficient to monitor for initial safety/tolerability and local 
infusion site reactions and for systemic reactions to infusion. Following discharge, the
following measures arebeing taken inthisprotocol toensurethesafety ofstudy
participants :
Participants will beinformed that they aretaking ananticoagulant asa
participant in this trial, and that this might increase the risk of bleeding as might 
occur in surgery, dental procedures, or strenuous exercise/contact [CONTACT_861180].
Participants will beexcluded ifthey have planned significant dental procedures,
including surgery, orother planned surgical procedures within duration of
participation in the trial.
Participants will berequired toavoid scheduling anynon- urgent/elective 
surgical ordental procedures, andtoavoid strenuous physical activity andcontact
[CONTACT_861181].
Participants willbeprovided with anidentification card andamedical alert
bracelet, both ofwhich identify them asparticipants inananti-coagulant
08BRCT
PRODUCT: MK-2060  32
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
research trial and, intheevent ofanemergency, willserve tonotify healthcare
providers that they might be atriskforprovoked bleeding.
Iflocal labaPTT values are> 3-fold above baseline, orlocal labPTvalues are>
1.5fold above baseline (atanytime point), participants willbeasked toremain in
theclinic foratleast 24 hours, anduntil aPTT/PT values arenolonger increasing
(upon retest )and at the discretion of the investigator .
Due to the physio- chemical properties of monoclonal antibody (mAb) therapeutics, transfer 
to the seminal compartment and subsequent vaginal uptake of a mAb is essentially zero, as 
demonstrated in rabbits, monkeys, and humans [Breslin, W. J., et al 2014] , [Moffat, G. J., et 
al 2014] , and [Sohn, W., et al 2015] .  In addition, in an embryofetal developmental toxicity 
study in pregnant rabbits administered MK -2060, there was no evidence of embryofetal 
lethality or teratogenicity up to 120 mg/kg/day (the highest dose evaluated; 1 dose QW for 2 
weeks) providing an estimated systemic exposure margin of 234-fold the observed AUC0 -
168hr of 63day•μg/mL after multiple [ADDRESS_1200352] participant (or their legally acceptable representative) 
provides documented informed consent . The overall study ends when the last participant 
completes the last study -related contact , withdraws consent , or is lost to follow -up (ie, the 
participant is unable to be contact[CONTACT_19379]) .
Astudy may be paused during review of newly availa ble preclinical/ clinical safety, PK , 
pharmacodynamic, efficacy, or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the study 
open for gathering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study. If necessary, the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the 
study following this review period, the study end will be defined as the date of the Sponsor 
decision, and this end of study date supersedes the definitions outlined above . The 
Competent Authority(ies) and IRB(s)/IEC(s) will be apprised of the maximum duration of 
the study beyond the last participant out and the justifica tion for keepi[INVESTIGATOR_88635].
4.4.[ADDRESS_1200353] on HD between the ages of 18 and 80 years 
(inclusive) will be enrolled in this study.
08BRCT
PRODUCT: MK-2060  33
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant meets all of the 
following criteria :
Type of Participant and Disease Characteristics
1. ESRD maintained on stable outpatient HD regimen at a healthcare center for > [ADDRESS_1200354] chronic HD access 
injuries, and HD stability defined as Kt/V ≥1.[ADDRESS_1200355] a Body Mass Index (BMI) ≥ 18 and ≤ 45 kg/m2. BMI = weight (kg)/height (m)2.
Dry weight (body weight after hemodialysis) should be used for BMI calculations.
5.Baseline health is judged to be stable based on medical history, physical examination, 
vital sign measurements and ECG performed prior to treatment alloc ation.
6.Liver function test (serum alanine aminotransferase [ALT] and aspartate 
aminotransferase [AST]) must be equal to or below 1.5X upper limit of normal (ULN) 
and deemed not clinically significant by [CONTACT_093] .
7.Be willing to comply with the trial restrictions (see S ection 5.3) for a complete summary 
of trial restrictions).
Demographics
8.Ismale or female , from 18years to 80years of age inclusive, at the time of providing
informed consent.
Female Participants
9.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies: 
•Not a WOCBP
08BRCT
PRODUCT: MK-2060  34
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercour se as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as described in Appendix [5] during the intervention period and for 
at least [ADDRESS_1200356] dose of study intervention. The investigator should 
evaluate the potential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_301792]
-Has a negative highly sensitive pregnancy test (urine or serum as required by [CONTACT_13125]) within [ADDRESS_1200357] 
cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required. In such cases, the participant must be excluded from participation if the 
serum pregnancy result is positive. Additional requirements for pregnancy testing 
during and after study intervention are in Section 8.5.5 .
-Medical history, menstrual history, and recent sexual activity has been reviewed by 
[CONTACT_93301] a woman with an early undetected 
pregnancy.
Informed Consent
10. The participant (or legally acceptable represen tative) has provide ddocumented
informed consent/assent for the study. The participant may also provide 
consent/assent for FBR. However, the participant may participate in the study without 
participating in FBR.
Additional Categories
Consent must bedocume nted by[CONTACT_321237]’s dated signature [INVESTIGATOR_4388] [CONTACT_321237]’s
legally acceptable representative’s dated signature [CONTACT_861196].
Acopy ofthesigned anddated consent form should begiven totheparticipant before
participation inthetrial.
The initial informed consent form, anysubsequent revised written informed consent form
and any written information provided totheparticipant must receive theIRB/ERC’s
approval/favorable opi[INVESTIGATOR_861157]. The subject or his/her legally acceptable
representative should beinformed inatimely manner ifnew information becomes available
thatmay berelevant totheparticipant’s willingness tocontinue participation inthetrial.
The communication ofthisinformation will beprovided anddocumented viaarevised
08BRCT
PRODUCT: MK-2060  35
PROTOCOL/AMENDMENT NO.: 008-[ADDRESS_1200358]’s dated
signature [CONTACT_861197][CONTACT_321237]’s legally acceptable representative’s dated signature.
Specifics about a trial andthetrial population willbeadded totheconsent form template at
theprotocol level.
Theinformed consent willadhere toIRB/IEC requirements, applicable laws andregulations
andSponsor requirements.
5.[ADDRESS_1200359] be excluded from the study if the participant meets any of the following 
criteria :
Medical Conditions
1.History of any clinically significant concomitant disease or condition (including 
treatment for such conditions) or diseases whose current condition is considered 
clinically unstable that, in the opi[INVESTIGATOR_871], could either interfere with the 
study drug, compromise interpretation of study data, or pose an unacceptable risk to the 
patient. Participants with a remote history of uncomplicated medical events (e.g.,
uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the 
last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the 
investigator.
2.Institutionalized ,mentally or legally incapacitated at the time of prestudy (screening) 
visit or expected during the conduct of the study or has a history of clinically significant 
psychiatric disorder in th e last [ADDRESS_1200360] had situational depression 
may be enrolled in the study at the discretion of the investigator.
3.History of cancer (malignancy), including adenocarcinoma,
Exceptions: (1) A dequately treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or (2) Other malignancies that have been successfully treated with 
appropriate follow up and therefore unlikely to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] (eg, malignancies that have 
been successfully treated ≥10years prior to the screening visit ).
4.Has blood coagulation test from local lab (aPTT, PT) ≥ 20 % outside of normal range in 
screening period (confirm ed by [CONTACT_861182]) ..
5.Any other clinically significant abnormalities in laboratory test results at screening that 
would, in the opi[INVESTIGATOR_871], increase the patient's risk of participation, 
jeopardize complete participation in the study, or compromise interpretation of study 
data.
6.Has a history of deep vein thrombosis or pulmonary embolism. Has a history of vascular 
access thrombosis within [ADDRESS_1200361]: MK-2060  36
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
bleeding disorder (e.g., hemophilia, Factor V Leiden, prothrombin gene mutation, protein 
C or S deficiency, ATIII deficiency, anti -phospholipid Ab syndrome).
7.Has a history of GI bleeding, duodenal polyps or gastric ulcer in the last [ADDRESS_1200362] 3 
months or active gingivitis prior to screening.
9.Atthetime ofscreening orpre-dose, hasplanned significant dental procedures
(including planned dental surgery), orother planned surgical procedures within duration 
of participation in the trial.
10.Is positive for hepatitis B surface antigen or HIV.  Participants positive for hepatitis C 
antibodies may be enrolled with agreement of both investigator and spon sor.
11.The participant had a major surgery and/or donated or lost 1 unit of blood (approximately 
500 mL) within 4 weeks prior to the screening visit
12.History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or 
has had an anaphy lactic reaction or significant intolerability (ie, systemic allergic 
reaction) to prescription or nonprescription drugs or food.
13.Has atattoo, scar, orother physical finding atthearea oftheinfusion site that would 
interfere with infusion or a local tolerability assessment.
Prior/Concomitant Therapy
14.Unable to refrain from or anticipates the use of any medication, including prescription 
and nonprescription drugs or herbal remedies (except clopodigrel) beginning 
approximately 2 weeks (or 5 half -lives) prior to administration of the initial dose of study 
intervention, throughout the study, until the poststudy visit. There may be certain 
medications that are permitted (see Section 6.5).
15.Has ongoing anticoagulant therapy (warfarin, api[INVESTIGATOR_3822], dabigatran, rivaroxaban, 
edoxaban, betrixaban) or antiplatelet ther apy which does notinclude clopi[INVESTIGATOR_7745] (ie. 
prasugrel, ticagrelor, ticlopi[INVESTIGATOR_5325] , and aspi[INVESTIGATOR_248] ). Intradialytic heparin ispermitted .
16.Has ahistory (subject recall) ofreceiving anyhuman immunoglobulin preparation
such as IVIG or RhoGAM within the last year.
17.Has ahistory (subject recall) ofreceiving anybiological therapy (including human
blood products ormonoclonal antibodies; excluding erythropoietin and insulin) within
thelast3months or5half-lives (whichever is longer), or vaccination within the last 
month.
08BRCT
PRODUCT: MK-2060  37
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Exceptions: 
Participants who have received seasonal flu vaccine and/or pneumococcal vaccine 
within one month prior to Day 1 dosing may be enrolled at the discretion of the 
investigator.
COVID -[ADDRESS_1200363] 48 hours prior to any COVID- 19 vaccination.
Investigational COVID -19 vaccines (i.e., those not licensed or approved for 
Emergency Use) are not allowed .
Prior/Concurrent Clinical Study Experience
18.Participated in another investigational study within 4 weeks (or 5 half-lives, whichever is 
greater) prior to the screening visit. The window will be derived from the date of the last 
dose in the previous study.
Diagnostic Assessments
19.Has a blood pressure > 190mmHg systolic or>110mmHg diastolic .
20.Exclusion criteria for ECG:
Heart rate < 40 or > 110 bpm 
QTc interval > 500 msec 
Any significant arrhythmia or conduction abnormality, (including but not specific to 
atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome 
[unless curative radio ablation therapy]), which, in the opi[INVESTIGATOR_710218] , could interfere with the safety for the individual patient.
Other Exclusions
21.Under the age of legal consent.
22.Consumes greater than 3 servings of alcoholic beverages (1 serving is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL/1 ounce]) per day. Participan ts who consume 4 servings of alcoholic beverages 
per day may be enrolled at the discretion of the investigator.
23.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately equivalent to 120 mg of caffeine) of coffee, tea, col a, energy drinks, or 
other caffeinated beverages per day.
24.Aregular user of cannabis, any illicit drugs or has a history of drug (including alcohol) 
abuse within approximately [ADDRESS_1200364]: MK-2060  38
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
physician prescribed medications (e.g., opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], antidepressants) may 
be enrolled at the discretion of the investigator.  In addition, participants with a positive 
THC may be enrolled at the discretion of the investigator if the participants’ THC use is 
under 4 times/month and the participants agree to not use during their study participation.  
Participants with positive THC on screening may have rechecks performed at the 
discretion of the investigator to ensure compliance with abstinence from THC use during 
study participation.
25.The investigator has a ny concern regarding safe participation in the study or for any other 
reason the investigator considers the participant inappropr iate for participation in the 
study.
26.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
[IP_ADDRESS] Diet Restrictions
Fasting requirements forlaboratory safety evaluations arespecified inSection 10.2.
All meals on study dosing days will be served as to not interfere with the study procedures.
Meals and snack(s) will be provided by [CONTACT_861183].
Participant swill be instructed to avoid ingesting certain foods (such as red meat, broccoli, 
turnips etc.) and certain medications and supplements (such as vitamin C supplements etc.) 
for about three days prior to f eces sample collection to avoid false positive hemoccult test .
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours before the prestudy and poststudy visits and from 12 hours prior to 
and after study intervention administration. At all other times, caffeinated beverages or 
xanthine -containing products will be limited to no more than 6 units per day (1unit= 120mg 
of caffeine).
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol [ADDRESS_1200365]: MK-2060  39
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
At all other times, alcohol consumption is limited to no more than approximately 3 alcoholic 
beverages or equivalent servings (1 serving is approximately equival ent to: beer 
[354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL/1 ounce]) per day.
[IP_ADDRESS] Tobacco Restrictions
Smoking (and/or the use of nicotine/nicotine -containing products) is permitted during the 
study. Participant should follow CRU’s smoking restrictions during domiciling.
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (ie, weight lifting, running, 
bicycling, etc) from the prestudy (screening) visit throughout the study and until the 
poststudy visit.
5.[ADDRESS_1200366] dosing, a replacement participant may be enrolled if deemed appropriate 
by [CONTACT_8981]. The replacement participant will generally receive the same 
intervention or intervention sequenc e (as appropriate) as the participant being replaced. The 
replacement participant will be assigned a unique treatment/randomization number.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placeb o, or me dical device(s) intended to be administered to a study participant according to 
the study protoco l.
Clinical supplie s MK-2060 will be packaged to support enrollment and replacement 
participants as required. When a replacement participant is require d, the Sponsor or designee 
needs to be contact[CONTACT_100915] . Clinical supplies will be 
affixed with a clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study are outlined inTable [ADDRESS_1200367]: MK-2060  40
PROTOCOL/AMENDMENT NO.: 008-01
MK-2060 -008-01 FINAL PROTOCOL 09-JUN-2022
Table 3 Study Intervention s
Arm 
NameArm 
TypeIntervention 
NameInter -
vention 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegimen/
Treatment Period/
Vaccination 
Regimen UseIMP/
NIMP Sourcing
MK-2060 Experi
mentalMK-2060 Drug Lyophilized 
Powder7.5 mg/vial 25 mg IV 
InfusionWeek 1: Days 1, 3, 
5
Week 2: Day 8Experi
mentalIMP Provided 
centrally 
by 
[CONTACT_2728] P
EEA =European Economic Area; IMP=investigational medicinal product; IV = intravenous; NIMP=noninvestigational medicinal product .
The classification of IMP and N IMP in this table is based on guidance issued by [CONTACT_861184] s in the E EA.Country differences with 
respect to the definition /classification of IMP/NIMP may exist. In these circumstances, local legislation is followed.
08BRCT
PRODUCT:   MK-2060  41
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
All supplies indicated in Table 3 will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/batch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storage/ Accountability
6.2.[ADDRESS_1200368] be stored 
in a secure, environm entally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where a pplicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropri ate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
08BRCT
PRODUCT:   MK-2060  42
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.[ADDRESS_1200369] udy; therefore, the Sponsor, investigator, and participant will know 
the intervention administered.
6.4 Study Intervention Compliance
Interruptions from the protocol -specified treatme nt plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during time periods specified by [CONTACT_151524] . If there is a 
clinical indication for any m edications or vaccinations specifically prohibited, 
discontinuation from study intervention may be required. The investigator should discuss any 
questions regarding this with the Sponsor Clinical Director . The final decision on any
supportive therapy or vaccination rests with the investigator and/or the participant ’s primary 
physician. However, the decision to continue the participant on study intervention requires 
the mutual agreement of the investigator, the Sponsor, and the participant.
Any medication or vaccine (including over -the-counter or prescription m edicines, vitamins, 
and/or herbal supplements or other specific categories of interest) that the participant is 
receiving at the time of enrollment or receives during the study must be recorded along with:
•Reason for use
•Dates of administration including start and end dates
•Dosage information including dose and frequency
The Sponsor Clinical Director should be contact[CONTACT_61519].
Concomitant use of the following medications will be allowed during the conduct of the 
study as long as the subject has been on a stable dose and treatment regimen for at least 
approximately [ADDRESS_1200370]:   MK-2060  43
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200371] dose of study drug. The name (generic and brand), dose 
and regimen for all concomitant medications should be recorded on the appropriate CRF. 
All medications must be reviewed and approved by [CONTACT_861185].  This list i s not exhaustive, but serves as a guideline to 
facilitate the approval process between the investigator and the Sponsor clinical monitor
ALLOWED MEDICATIONS
Lipid Lowering Agents: Statins
Atorvastatin 
Simvastatin 
Pravastatin 
Lovastatin
Rosuvastatin
Pravastatin 
Lipid Lowering Agents: Fibrates
Fenofibrate 
Gemfibrozil
Lipid Lowering Agents: Other
Ezetimibe
Anti -Hypertensive Medications:
Monotherapy and combination therapy with an angiotensin converting enzyme (ACE) 
inhibitor, an angiotensin II receptor antagonist, beta blockers, calcium channel blockers, or a 
diuretic is allowed in the study.
Specific therapeutic categories include:
1. ACE inhibitors
Benazepril 
Captopril
Enalapril
Fosinopril
Lisinopril 
Moexipril 
Perindopril
Quinapril 
Ramipril 
Trandolapril
08BRCT
PRODUCT:   MK-2060  44
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
2. Angiotensin II Receptor Antagonists
Candesartan
Eprosartan 
Irbesartan
Olmesartan
Telmisartan 
Valsartan 
3. Diuretics
Hydrochlorothiazide 
Chlorothiazide 
Amiloride 
Triamterene 
Spi[INVESTIGATOR_861158]- diuretics, e.g., furosemide
4. Beta -blockers
5. Calcium channel -blockers
Diabetes Medications 
Specific therapeutic categories include: 
1. Insulin 
2. Metformin
3. Sulfonylureas 
Glipi[INVESTIGATOR_861159]
4. Meglitinides 
Repaglinide
Nateglinide 
5. Thiazolidinediones
Pi[INVESTIGATOR_861160]
08BRCT
PRODUCT:   MK-2060  45
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
6. DPP- 4 Inhibitors
Linagliptin 
Saxagliptin 
Sitagliptin 
Vildagliptin
7. GLP -1 Analogs
Exenatide
Liraglutide
Iron 
Phosphate Binders 
Vitamin D 
Erythropoietin
PROHIBITED MEDICATIONS
Listed below are specific restrictions for concomitant therapy during the course of the trial, 
from signing consent to the poststudy visit:
Oral Anticoagulants (Intradialytic heparin is permitted in the study)
Warfarin
Api[INVESTIGATOR_861161] (e.g., i buprofen ); however ,the non -NSAID paracetamol/acetaminophen may be 
used for minor ailments without prior consultation with the Sponsor.
6.5.[ADDRESS_1200372]:   MK-2060  46
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
CRUs will be staffed with m edically trained personnel with appropriate access to full service 
acute -care hospi[INVESTIGATOR_210631].
6.6 Dose Modification (Escalation/Titration/Other)
The dose and administration of the study intervention to any par ticipant may be modified
based on newly available safety, tolerability, pharmacokinetic and/or pharmacodynamic data 
observed in other MK -[ADDRESS_1200373] of this study.
If any of the below stoppi[INVESTIGATOR_26501], the study will be paused, and no further dosing 
will occur until the Sponsor has reviewed the totality of data available. To continue the study 
(on joint agreement with the Sponsor and investigator), a substantial amendment will be 
submitted for approval.
1.An individual participant reports an SAE considered related to the study intervention 
by [CONTACT_093].
2.Two (2) or more participants report Severe Nonserious AEs considered related to the 
study intervention by [CONTACT_093].
3.If one or more treatment -related infusion adverse events of severe intensity occurs in 
2 or more participants.
4.An increase in local lab aPTT >4.0- fold versus screening baseline as confirmed after 
repeat measurement in 2 or more participants. Local lab aPTT measured at the 
Screening Visit should be used as baseline value.
5.An increase in local lab PT >1.5- fold versus screening baseline as confirmed afte r 
repeat measurement in [ADDRESS_1200374] been 
observed [Asakai, R., et al 1991] .Using the same PD aPTT assay utilized in PN001 and to be 
used by [CONTACT_861186], samples of pooled normal human plasma were compared 
to those from FXI -deficient patients, which were tested individually [Ellsworth K 2018].  In 
normal human plasma, the clot time ranged between 31.8 and 36.4 seconds.  In plasma from 
FXI deficient patients, the clot time ranged between 99.5 and 128.1 seconds, which 
corresponded to a range of 2.9 to 3.9- fold prolongation in aPTT compared to that of the 
normal human plasma.  From data collected in PN001, it appears that higher doses of MK-
2060 provide similar inhibition as the severe FXI -deficient phenotype, evidenced by [CONTACT_90338] -
2060- associ ated increases in aPTT (local lab) up to 3.[ADDRESS_1200375] dose in PN001
(120 mg administered subcutaneously).  These aPTT prolongations occurred in the absence 
08BRCT
PRODUCT:   MK-2060  47
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
of prolongation of PT and were associated with >95% inhibition of FXI activity, with no 
evidence of MK -2060- related AE. Therefore, the stoppi[INVESTIGATOR_861162] >[ADDRESS_1200376] -dose timepoint (heparin t1/2 is ~1hr).  All 
other local safety labs throughout the course of the trial will be dr awn pre -hemodialysis and 
in the absence of heparin.
The safety of participants will be assessed on an ongoing basis, and while conditions that 
could warrant stoppi[INVESTIGATOR_861163], these criteria are meant 
to pre -specify circu mstances under which the trial may be stopped to review the available 
safety data.  Importantly, if any criterion listed above occurs, further dosing will be stopped 
and review ofavailable safety data by [CONTACT_861187], which might include modification of safety monitoring procedures.  
6.7 Intervention After the End of the Study
There is no study -specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
This study is open- label ; therefore, the participant, the study- site personnel, the Sponsor, 
and/or designee are not blinded. Study intervention (name, strength, or potency) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
6.[ADDRESS_1200377] be collected through the participant’s last scheduled follow -up, even if 
the participant has discontinued study intervention. Therefore, all participants who 
discontinue study intervention beforecompletion of the protocol -specified treatment period 
08BRCT
PRODUCT:   MK-2060  48
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200378] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is v iolated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.9.
A participant must be discontinued from study intervention ,but continue to be monitored in 
the study, for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirmed positive serum pregnancy test.
•The participant has a positive drug screen at any tim e during the course of the study and 
after confirmation by [CONTACT_861182] .
7.[ADDRESS_1200379] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specifi c det ails regarding withdrawal from FBR ,are outlined in Section 
8.1.9. The procedures to be performed should a participant repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
08BRCT
PRODUCT:   MK-2060  49
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200380] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every effort to regain contact [CONTACT_618278] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study- site personnel responsibilities will be docu mented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be u sed for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessary by [CONTACT_791331] t o participant safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evalu ations/testing will be performed in accordance with those regulations.
08BRCT
PRODUCT:   MK-2060  50
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
The maximum amount of blood collected from each participant over the duration of the study
will not exceed ~453mL(Appendix 8).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative ) prior to participating in thisclinical study or FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the i nvestigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
[IP_ADDRESS] General Informed Consent
Informed c onsent given by [CONTACT_19429] a consent f orm. The form must include the study protocol number, study 
protocol title, dated signature , and agreement of the participant ( orhis/her leg ally acceptable 
representative ) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s dated 
signature.
Specifics about the study and the study population are to be included in thestudy informed
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
[IP_ADDRESS] Consent and Collect ion of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
08BRCT
PRODUCT:   MK-2060  51
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
to FBR. A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_1200381] information (including direct 
telephone numbers) to be used in the event of an emergency. The inve stigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention alloc ation,
site personnel will add the treatment /randomi zation number to the participant identification 
card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404].
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] 28 days before starting the study.
[IP_ADDRESS] Concomitant Medications
The invest igator or qualified designee will record medication, if any, taken by [CONTACT_19432].
8.1.[ADDRESS_1200382]:   MK-2060  52
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
8.1.7 Assignment of Treatment/ Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation. Once a 
treatment /randomization number is assigned to a participant, it can neve r be reassigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Study intervention(s) will be administered by [CONTACT_1755]/or study staff according to 
the specifications within the pharmacy manual .
[IP_ADDRESS] Timing of Dose Administration
MK-[ADDRESS_1200383] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study and/or intervention. If a participant discontinues for 
any reason at any time during the course of the study, the participant may be asked to return 
to the clinic (or be contact[INVESTIGATOR_530]) for a poststudy visit as per the number of days described in
Section 8.11.[ADDRESS_1200384] the applicable procedures conducted. However, the investigator may 
decide to perform the poststudy procedures at the time of discontinuation or as soon as 
possible after discontinuation. If the poststudy visit occurs prior to the safety follow- up time 
frame as specified in Section 8. 5.1, the investigator should perform a follow- up telephone 
call at the end of the follow -up period (Section 8.5 .1) to confirm if any AEs have occurred 
since the poststudy clinic visit. Any AEs that are present at the time of 
discontinuation/withdrawal should be followed in accordance with the safety requirements 
outlined in Section 8. 5.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for FBR . Participants may withdraw consent at any 
time by [CONTACT_88690]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
(clinical.specimen.management@ MSD .com). Subse quently, the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any anal yses in progress at the time of request for withdrawal or 
already performed before the request being received by [CONTACT_508228] 
08BRCT
PRODUCT:   MK-2060  53
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200385] is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a l ink between the participant’s personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed .
8.1.10 Participant Blinding/Unblindi ng
This is an open -label study; there is no blinding for this study. The emerge ncy unblinding 
call center will be available so that a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available .
8.1.[ADDRESS_1200386] of the participant , participants may  remai n in 
the CRU longer . 
8.1.12 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclu sion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
Critical Equipment for this trial includes:
Infusion pumps
VS and ECG instruments
All equipment to process study drug and samples, such as but not limited to, 
centrifuge equipment, pi[INVESTIGATOR_6343], and freezers for MK -2060 and sample storage.
8.2 Efficacy/Immunogenicity Assessmen ts
The amino acid sequence of MK -[ADDRESS_1200387] immune response. 
Following analysis for ADA from PN001, o ne outof 45 (2.2%) had positive ADA test result 
([ADDRESS_1200388] dose time point) . The presence of ADA did not appear to 
08BRCT
PRODUCT:   MK-2060  54
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200389] 
affected the current PK profiles. Therefore, the overall risk of immunogenicity is expected to 
be low for MK- 2060.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of bloo d/tissue to be drawn/collected over the course of the study 
(from prestudy to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_113802], can be found in Appendix 8. 
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) per institutional standard. Height and weight 
will also be measured and recorded.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
[IP_ADDRESS] Body Weight and Height
Body height and weight will be obtained with the subjects shoes off, jacket or coat removed.
[IP_ADDRESS] Body M ass Index (BMI)
BMI equals a person's weight in kilograms divided by [CONTACT_55739] 
(BMI=kg/m2). BMIwill be rounded to the nearest whole number according to the standard 
convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Dry weight (body weight after hemodialysis) should be used for BMI calculations.
8.3.2 Vital Signs
•Body temperature, HR, RR, and B P will be assessed.
•BP and pulse measurements will be assessed semi -recumbent with a completely 
automated device. Manual techniques will be used only if an automated device is not 
available.
08BRCT
PRODUCT:   MK-2060  55
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
•VSwill be measured in a semi -recumbent position after at least [ADDRESS_1200390] and will 
include temperature, systolic and diastolic BP, and pulse and RR.
[IP_ADDRESS] Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a quiet setting without distra ctions in a semi -recumbent
position for at least [ADDRESS_1200391] positioning on the 
participants' arm is essential to increase the accuracy of BP measurements.
The Day 1 predose (baseline) resting HR and BP will be in triplicate measurements, obtained 
at least 1 to 2 minutes apart within 3 hours of dosing MK-2060. The median of these 
measurements will be used as the baseline to calculate change from baseline for safety 
evaluations (and for rechecks, if needed). All other VS measurements will be single 
measurements.
Participants will continue to rest semi -recumbent from dosing until [ADDRESS_1200392] be used for all measurements for 
each individual participant and should be the same for all participants at a given site.
Respi[INVESTIGATOR_861164] (breaths per minute) will be measured and re corded as single measurements.
[IP_ADDRESS] Orthostatic Vital Signs
Orthostatic VS (HR and systolic and diastolic BP) will also be obtained. Participants should 
be semi -recumbent for at least [ADDRESS_1200393]:   MK-2060  56
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200394] 1 to 2 minutes apart within 
3hours before dosing MK -2060. The median of these measurements will be used as the 
baseline to calculate change from baseline for safety evaluations (and for rechecks, if 
needed). Unless otherwise designated in the flow chart, all other ECG measurements will be 
single measurements.
If a participant demonstrates an increase in QTc interval ≥60msec compared with median 
predose baseline measurement, the ECG will be repeated twice within 5 minutes. The median 
value of the QTc interval from the 3 ECGs will represent the value at that time point. If the 
median QTc interval increase from baseline for any postdose time point is ≥[ADDRESS_1200395] 1 hour or until the QTc is within 60 msec of baseline. If prolongation of the QTc 
interval ≥[ADDRESS_1200396] may be appropriate and 
the Sponsor should be notified.
If the median QTc interval is ≥[ADDRESS_1200397]. T he participant should be telemetry monitored ( until 
the QTc is <500 msec) or should be considered for transfer to a location where closer 
monitoring and definitive care (eg, a CCU or ICU) is available.
If the participant has unstable hemodynamics, or has any clinically significant dysrhythmias 
noted on telemetry, the participant should be immediately transferred to an acute care setting 
for definitive therapy.
If prolongation of the QTc is noted, concomitant medications that prolong QTc shou ld be 
held until the QTc is within 60 msec of baseline and the QTc is <[ADDRESS_1200398]:   MK-2060  57
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200399] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laborator y 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448] ’s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_1200400] be 
conducted in accordance with the laboratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tes ts with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_1200401] -dose. An anaphylactic reaction is a 
severe type of infusion reaction that is characterized by [CONTACT_861188], 
such as generalized hives, pruritis or flushing, swollen lip -tongue -uvula and angioedema, 
accompanied by [CONTACT_15206][INVESTIGATOR_7798] (bronchospasm, stridor or hoarseness) and/or 
changes in blood pressure (hypotension). Severe infusion reactions, including cytokine 
release syndrome and hypersensitivity reactions must be promptly treated with interruption 
08BRCT
PRODUCT:   MK-2060  58
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200402] -dose 
at CRU after the initiation of administration. During this time, signs and symptoms of a 
systemic injection/infusion reaction, including but no limited to fever, VS changes 
(tachycardia/hypotension), pruritis, urticarial (hives), lip swilling, angioedema, 
bronchospasm, stridor, hoarseness, and shortness of breath will be monitored. 
Injection/infusion reactions must be assessed and managed promptly. 
8.4.2 Local Infusion Rea ction Assessment
A local infusion site examination will be obtained as outlined in Section 1.3 and will include 
an assessment of any pain, tenderness, erythema/redness and induration/swelling. These 
events will be evaluated based upon the system outlined i n the guidance for the industry 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials in Table [ADDRESS_1200403] be assessed and managed 
promptly per site procedure.
Participants who call the CRU to report an infusion site reaction within 7 days postdose may 
be asked to return to the CRU as soon as possible for an additional local infusion si te reaction 
assessment.
Table 4 Local Infusion Reaction Assessment
Local Site 
ReactionMild Moderate SeverePotentially Life
Threatening
Pain Does not 
interfere with 
activityRepeated use of non -
narcotic pain reliever > 
24 hr or inte rferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityEmergency room (ER) 
visit or hospi[INVESTIGATOR_861165]/
Redness2.5-5 cm 5.1 –10 cm > 10 cm Necrosis or exfoliative 
dermatitis 
Induration/
Swelling2.5 –5 cm and 
does not 
interfere with 
activity5.1 –10 cm or 
interferes with activity> [ADDRESS_1200404]:   MK-2060  59
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
8.5 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and ot her reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and r eporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8. 5.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.5.[ADDRESS_1200405] be reported by [CONTACT_508230]:
•if the participant is receiving placebo run -in or other run -in treatment,
•if the event causes the participant to be excluded from the study,
•if it is the result of a protocol -specified intervention, including ,but not limited to washout 
or discontinuation of usual therapy, diet, placebo, or a procedure.
From the time of intervention allocation through ~[ADDRESS_1200406] be reported immediately to the Sponsor if the 
event is considered related to study inter vention.
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged fro m the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be record ed and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_1200407]:   MK-2060  60
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of 
EventReporting Time Period:
Consent to Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
specified Follow -
up PeriodReporting 
Time Period:
After the 
Protocol -
specified 
Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Information 
to Sponsor:
NSAE Report if:
-due to protocol -specified 
intervention
-causes exclusion
-participant is receiving placebo 
run-in or other run -in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -specified 
intervention
-causes exclusion
-participant is receiving placebo 
run-in or other run -in treatmentReport all Report if:
-drug/vaccine 
related.
(Follow 
ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/
Lactation 
ExposureReport if:
- participant has been exposed to 
any protocol -specified intervention 
(eg, procedure, washout or run -in 
treatment including placebo run -in)
Exception: A positive pregnancy 
test at the time of initial screening 
is not a reportable event.Report all Previously 
reported –
Follow to 
completion/
termination; 
report 
outcomeWithin 24 
hours of 
learning of 
event
ECI (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-potential DILI
-require regulatory 
reportingNot required Within 24 
hours of 
learning of 
event
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs 
and those not 
requiring regulatory 
reportingNot required Within 5 
calendar days 
of learning of 
event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
(unless 
serious)
Overdose Report if:
-receiving placebo run -in or other 
run-in medication Report all Not required Within 24 
hours of 
learning of 
event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
even t.
08BRCT
PRODUCT:   MK-2060  61
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
8.5.2 Method of Detecti ng AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.5.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report , the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in allocated participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.5.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study intervention under clinical investigation are m et.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requireme nts and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if ap propriate according to local requirements .
8.5.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an ele ctive termination of a 
pregnancy will be reported as an SAE for the fetus.
08BRCT
PRODUCT:   MK-2060  62
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200408] be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.5.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.
8.5.[ADDRESS_1200409] for this study include:
1.An overdose of Sponsor's product, as defined in Section 8. 6.
2.An elevate d AST or ALT laboratory value that is greater than or equal to 3X the ULN 
and an elevated total bilirubin laboratory value that is greater than or equal to 2X the 
ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X 
the ULN, as determined by [CONTACT_13149] -specified laboratory testing or unscheduled 
laboratory testing.*
*Note: These criteria are based on available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tes ts that may require an 
additional evaluation for an underlying etiology. The study -site guidance for assessment 
and follow up of these criteria can be found in the Investigator Study File Binder (or 
equivalent).
It may also be appropriate to conduct additional evaluation for an underlying etiology in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
8.[ADDRESS_1200410]:   MK-2060  63
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
8.7 Pharmacokinetics
The decision as to which plasma and/or urine samples collected will be measured for 
evaluation of PK/pharmacodynamics will be collaboratively determined by [CONTACT_1034] (eg, 
samples at lower doses may not be measured if samples at higher doses reveal undetectable 
drug concentrations). If indicated, these samples may also be measured and/or pooled for 
assay in an exploratory manner for metabolites and/or additional pharmacodynamic markers .
8.7.1 Bloo d Collection for Plasma MK -2060 and Clopi[INVESTIGATOR_861166], storage, and shipment instructions for plasma samples will be provided in 
the Study Operations Manual by [CONTACT_1034] .Samples taken on the day of infusion will be 
collected in the opposite arm from the infusion site. The 1 -hour PK sample will be obtained 
immediately prior to the end of infusion (i.e. no more than 15 min before anticipated time of 
the end of infusion). Asplasma concentrations of the parent compound of c lopi[INVESTIGATOR_861167] 2 hours after dosing, 
concentrations of the main circulating metabolite clopi[INVESTIGATOR_861168] r clopi[INVESTIGATOR_60469] . 
8.8 Pharmacodynamics
Sample collection, storage, and shipment instructions for PT/aPTT/ FXI activity by [CONTACT_861189].
8.9 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA .
8.9.1 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample will be drawn for CYP2C19 genotypi[INVESTIGATOR_88645]. If the 
IRB/IEC does not approve of the planned analysis of the association between DNA variation 
and drug response, or if there is a local law or regulation prohi biting the same, data analysis 
will be limited to CYP2C19.  Leftover extracted DNA will be stored for FBR if the 
participant provides documented informed consent for FBR. 
Sample collection, storage, and shipment instructions for planned genetic analysis s amples 
will be in the Operations/Laboratory Manual.
8.9.2 Blood Collection for PT, aPTT, FXI Activity
PT and aPTT at screening, predose, and postdose specified in the SoA will be performed 
locally for safety monitoring. All other predose and postdose PT and aPTT, as well as FXI
activity will be performed at a central vendor for PK/PD analysis. Sample collection, storage, 
and shipment instructions for the PT, aPTT, FXI activity will be provided in a separate Study 
08BRCT
PRODUCT:   MK-2060  64
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Operations Manual by [CONTACT_1034]. The primary data for statistical analysis and modeling 
will be based on the information from the central vendor.
8.9.3 Blood for Plasma ADA
Sample collection, storage, and shipment instr uction for plasma samples will be provided in a 
separate Study Operations Manual by [CONTACT_1034].
8.10 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the following specime ns 
will be obtained as part of FBR :
Leftover DNA for future research.
Leftover main study plasma for future researc h.
8.11 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details areprovided 
inSection 8.
8.11.1 Screening and Run -in Period
Screening Visit:
Within 6weeks before intervention alloc ation, potential participants will be evaluated to 
determine that they fulfill the entry requirements as set forth in Section 5.
Participants may be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. 
Run-in Period:
Approximately 14 days before intervention allocation, potential participants who meet 
inclusion/exclusion criteria at the Screening Visit will report to the clinical research unit to 
perform on site hemodialysis on the days per SoA. Baseline Time to hemostasis will be 
measured during the run -in period .Refer to the SoA for other p rocedures required for the 
run-in period.
8.11.2 Treatment Period
Refer to the Schedule of Activities (Section 1.3) and Administrative and General Procedures 
(Section 8.1).
After all predose procedures have been completed, participan ts will be assigned a unique 
allocation number in a computer -generated allocation schedule. 
08BRCT
PRODUCT:   MK-2060  65
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200411] 
dose of study drug. Procedures outlined in the poststudy visit may be obtained on Day 1 04
(±7 days). However, follow up on any clinical or laboratory AEs should occur in person if 
the poststudy visit occurs prior to 96days following administration of the last dose of study 
drug.
8.11.4 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Stud y
At any point if a participant discontinues from treatment but continues to be monitored in the 
study, all of study procedures specified in the SoA may be completed upon joint agreement 
between the investigator and the Sponsor . The subset of study procedures completed will be 
communicated in a PCL.
8.11.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study, the blood sample for MK- [ADDRESS_1200412] time point as possible. All other procedures should be completed as close to the 
prescribed/scheduled time as possible. Study procedures can be performed before or after the 
prescribed/scheduled time.
The order of priori ty can be changed during the study with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure co llection times will be permitted.
•Postdose PK and PD sample collection, standard safety evaluation s(VS, ECG, laboratory 
safety tests (including chemistry/hematology, aPTT, PT) ,physical exam (full, symptom 
driven, systemi c injection/infusion, local injection/infusion) )as outlined in 
Table [ADDRESS_1200413]:   MK-2060  66
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Table 6 Pharmacokinetic (Blood) , Pharmacodynamic and Biomarker Collection Windows
PK, PD and ADA Collection PK, PD and ADA Collection Window
Days 1, 3, 5, 8: predose Within 2hr of dosing (samples to be 
collected before dialysis)
Day 1, 3, 5, 8 :[ADDRESS_1200414] each dose ± 15 min (within 15 min ofend of infusion )
Days 1, 3, 5, 8 :[ADDRESS_1200415] dose ± 30 min
Days2, 9,10 ± 4 hr of theoretical sampling time
Days 12, 15, 21, 2 9, 35 ± 1 day 
Days 49, 67 ± 3 days 
Day 104 ± 7 days 
•Predose standard safety evaluations: VS and ECG within 3 hours of MK -2060 dosing; 
laboratory safety tests (including aPTT and PT at local lab), drug screen and physical 
exam within [ADDRESS_1200416] Safety Evaluations (VS, 
ECG, laboratory safety tests, and physical 
exam)Postdose Evaluation Window
Days 1, 3, 5, and 8: all postdose ± 30 min of theoretical sampling time
Days 2, 9, and 10 ± 4hr of theoretical sampling time
Days 12, 15, 21, 29 , 35 ± 1 day 
Days 49, 67 ± 3 days 
Day 104 ± 7 days  
•Assessment of time to adequate hemostasis: at the conclusion of the onsite hemodialysis 
session, after hemodialysis catheters are removed from the dialysis access site.
•Hemoccult test : samples may be obtained within [ADDRESS_1200417] 
available sample if not within th e specified time window.
•Postdose evaluations: weight (Day 104), seru m or urine pregnancy test (Day 104): use 
windows indicated in Table 7.
•Study intervention administration: +/-1 hour relative to time of dosing on Day 1.
•Run-in (Day - 14 to Day -3 Visits): ± [ADDRESS_1200418]:   MK-2060  67
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
8.11.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase [ADDRESS_1200419] on HD , and the PK, 
pharmacodynamic, and safety profiles of the compound arestill being elucidated. This 
protocol is written with some flexibility to accommodate the inherent dynamic nature of 
Phase 1 clinical studies. Modifications to the dose, dosing regimen, and/or clinical or 
laboratory procedures currently outlined may be required to achieve the scientific goals of 
the study and/or to ensure appropriate safety monitoring of the study participants.
As such, some alterations from the currently outlined dose and/or dosing regimen may be 
permitted based on newl y available data, but the maximum daily dose may not exceed those 
currently outlined in the protocol.
•Decrease in the duration of study intervention administration (eg, number of days)
•Adjustment of the dosing interval (eg, divided doses [ bid to qd, qd to bid , tid, or vice 
versa])
•Lengthening of the washout period between doses
•Addition of PK pause
•Instructions to take study intervention with or without food or drink may also be modified 
based on newly available data
•Modification of the PK/pharmacodynamic sample processing and shippi[INVESTIGATOR_508216]/pharmacodynamic sampling scheme currently outlined in the protocol may be 
modified during the study based on newly available PK or pharmacodynamic data (eg, to 
obtain data closer to the time of peak plasma concentrations). If indicated, these collected 
samples may also be assayed in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
Up to additional 50 mL of blood may be drawn for safety, PK, an d/or pharmacodynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
The timing of procedures for assessment of safety proced ures (eg, vital signs, ECG, safety 
laboratory tests, etc) may be modified during the study based on newly available data. 
Additional laboratory safety tests may be added to blood samples previously drawn to obtain 
additional safety information. These chang es will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current study may usesome or none of the alterations described 
above. Any alteration made to this protocol to meet the study objectives must be detailed by 
08BRCT
PRODUCT:   MK-2060  68
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
the Sponsor in a letter to the Study File and forwarded to the investigator for retention. The 
letter may be forwarded to the IRB/IEC at the discretion of the investigator .
[ADDRESS_1200420] of presenting the descriptive statistics in shape of appropriate plots and summary 
tables (mean, standard deviation, median, min, max). 
9.[ADDRESS_1200421] auspi[INVESTIGATOR_26338], the Early Clinical Development Statistics Department in colla boration 
with the Quantitative Pharmacology and Pharmacometrics Department and Translational 
Pharmacology Department of the Sponsor.
If, after the study has begun, changes are made to the statistical analysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical Study Report.
9.3 Hypotheses/Estimatio n
Objectives of the study are stated in Section 3.
Primary Objective :To assess the safety and tolerability following multiple doses of 
concomitant treatment of MK -2060 and clopi[INVESTIGATOR_861169] 1:To evaluate plasma pharmacokinetics of MK- 2060 and 
clopi[INVESTIGATOR_861170]- 2060 and 
clopi[INVESTIGATOR_861171]:
Estimate plasma AUC0- 168, Cmax, C168, Tmax, terminal t1/2, CL, Vz. 
Secondary Objective 2: To determine whether the increase in time required to 
achieve hemostasis in ESRD patients treated with MK-2060 and following 
completion of dialysis remains below 20 minutes 
Hypothesis:
Mean time -to-hemostasis for MK -[ADDRESS_1200422]:   MK-2060  69
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Tertiary/Exploratory Objective 1: To explore the effect of concomitant treatment 
of MK -2060 and clopi[INVESTIGATOR_861147].
Estimation:
Estimate aPTT fold change from baseline .
Tertiary/Exploratory Objective 2:To explore the effect of concomitant treatment 
of MK -2060 and clopi[INVESTIGATOR_861148].
Estimation:
Estimate PT fold change from baseline.
9.4 Analysis Endpoints
Primary Endpoints
1.Safety and tolerability following multiple doses of concomitant treatment of MK -
2060 and clopi[INVESTIGATOR_861172]. Thus all AEs including bleeding 
related AEs (as defined in Section [IP_ADDRESS]) are the primary endpoints for this study .
Secondary Endpoints (Pharmacokinetic)
1.Pharmacokinetics: The pharmacokinetic variables of secondary interest for MK- 2060 
are plasma AUC0 -168, Cmax, C168 , Tmax, terminal t1/2, CL ,andVz.
2. Time to hemostasis
Exploratory Endpoints:
1.Pharmacodynamics: The PD variable of exploratory interest is aPTT (change from 
baseline). Baseline is defined as the pre -dose value.
2.ADA
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data.  All subjects 
will be reported, and their data analyzed, according to the treat ment(s) they actually received.
All Subjects as Treated: The All Subjects as Treated Population consists of all subjects who 
received at least on e dose of treatment.  This population will be used for assessments of 
safety and tolerability.
Per-Protocol : The Per -Protocol Population consists of the set of data generated by [CONTACT_861190] t these data will be likely 
to exhibit the effects of treatment, according to the underlying scientific model. Compliance 
08BRCT
PRODUCT:   MK-2060  70
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
covers such considerations as exposure to treatment, availability of measurements and 
absence of important protocol deviations. Impor tantprotocol deviations will be identified to 
the extent possible prior to unblinding by [CONTACT_100935]/compliance, and its analysis and interpretation.  Any subjects or data values 
excluded from analysis will be identified, a long with their reason for exclusion, in the CSR.  
At the end of the study, all subjects who are compliant with the study procedure as 
aforementioned and have available data from at least one treatment will be included in the 
Per-Protocol dataset. 
9.[ADDRESS_1200423] ical Methods
Safety 
Summary statistics and plots will be generated for raw laboratory safety tests, ECGs, and/or 
VS as well as for change from baseline, as deemed clinically appropriate.  For the primary 
endpoint, i.e., the bleeding related AEs, descripti ve summary ( total counts, percentage) will 
be provided. Same will be provided for all AEs as well as for the secondary and exploratory 
endpoints wherever appropriate. For continuous measurements, mean, standard deviation, 
median, min, max will be provided. Depending on the safety parameter, the difference from 
baseline will either be computed on the original scale (raw change from baseline) or on the 
log scale and back- transformed for reporting (percent change from baseline) as appropriate . 
Values wil l be l isted for each PK parameter (including Tmax and apparent terminal t1/2) , and 
appropriate non -model based descriptive statistics will be provided .
Secondary Hypothesis:
To determine whether the mean time-to-hemostasis recorded from patients treated with MK -
2060 is lower th an the cut- off time of 20 minutes, a Bayesian approach will be used. 
Utilizing a non- informative flat prior, the posterior probability that the observed mean of 
time-to-hemostasis of participants is less than 20 will be calculated, and the criteria for 
success will be met if the following condition is satisfied. 
Posterior -probability (PP) ( µTH<20) ≥ 0.60
Where 
µTH= mean of the time-to-hemostasis measurements for ESRD patients treated with MK -
2060
MK-2060 PK par ameters including plasma AUC0- 168, Cmax, C168, Tmax, terminal t1/2, 
CL, Vz with the following (non -model -based) descriptive statistics will be provided: N 
(number of subjects with non- missing data), geometric mean, and geometric percent CV 
(calculated as 100 x sqrt(exp(s2 ) -1), where s2 is the observed variance on the natural log -
scale) . 
08BRCT
PRODUCT:   MK-2060  71
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Exploratory Estimation:
Descriptive statistics as well as appropriate plots will be displayed for aPTT fold change 
from baseline. To describe the subject distribution using a contingency table for various time -
to-hemostasis measurement s with resp ect to treatments by [CONTACT_8311][INVESTIGATOR_861173]+MK -
2060, respectively. 
Time -to-hemostasis (mins) Clopi[INVESTIGATOR_861174] + MK -2060
<10
10-20
> 20
9.7 Interim Analyses
No interim analysis is planned for this study. 
9.8 Multiplicity
Since there are no pre -specified primary hypotheses, no adjustments for multiplicity are 
needed.
9.9 Sample Size and Power Calculations
Approximately 12 subjects will be enrolled for this study. The success criterion is that the 
posterior probability (PP) for the mean time -to-hemostasis less than 20 min, is greater tha n 
60%. Based on the assumed prior mean and standard deviation calculated from data f or MK-
2060- 004, the PP is calculated based on 10,000 simulations ,and is found to be r easonably 
high (>X%) that PP is above 60%. 
08BRCT
PRODUCT:   MK-2060  72
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1200424] for Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and ef fectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overr iding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH -GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventiona l investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . All trial protocols are and will be assessed for the need and capability to enroll 
underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD ’s clinical trials are conducted globally in many different countries and in diverse populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of facilities 
and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial i nitiation, 
sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability to 
successfully conduct the trial.
08BRCT
PRODUCT:   MK-2060  73
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts 
to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage 
underrepresented groups and those disproportionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately 
use the products under investigation.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incide nts/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothes is testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations publishe d by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independ ent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protoc ol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes t o the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant saf ety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Partic ipants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
08BRCT
PRODUCT:   MK-2060  74
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200425] extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay inc entives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may c ompensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investiga tor or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standar ds.
10.1.2 Financial Disclosure
Financial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor ’s responsibility to determine, based on these regulations, whether a request for 
financial d isclosure information is required. It is the investigator ’s/subinvestigator ’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_861191] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide thi s information on a 
Certification/Disclosure Form, frequent ly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
08BRCT
PRODUCT:   MK-2060  75
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200426] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transfer red.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed th at his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the exten t that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory a uthority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF informa tion, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_861192] n ames 
08BRCT
PRODUCT:   MK-2060  76
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
10.1.[ADDRESS_1200427] 
proprietary inform ation and to provide comments.
Authorship will be determined by [CONTACT_11403] I CMJE authorship 
requirement s.
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www .clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clini cal trials directive mandated trials . 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_861193] -site contact [CONTACT_3031].
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to those 
registries.
10.1.[ADDRESS_1200428] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, I CH GCP: Consolidated Guideline and other generally accepted standards of GCP ); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical study.
08BRCT
PRODUCT:   MK-2060  77
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200429] for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inf orm the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations re sulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, labor atory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and a udit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
08BRCT
PRODUCT:   MK-2060  78
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accor dance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent , pertaining to 
the conduct of this study must be reta ined by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No recor ds may be transferred to another location or party without written 
notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/i nstitution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Al so, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws,
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08BRCT
PRODUCT:   MK-2060  79
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 8will be performed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 8 Protocol -require d Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelet Count RBC Indices:
MCV
MCH
ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
ChemistryaBUN Potassium AST/SGOT Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
above the ULN)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium ALT/SGPT Total Protein
Glucose Calcium Alkaline 
phosphatase
Other Screening 
Tests•aPTT, PT (collection according to the trial schedule of activities Section 1.3 for 
aPTT and PT collected at local lab)
•FSH (as needed in WONCBP only)
•Serum or urine β human chorionic gonadotropin (β hCG) will be carried out on Day 
[ADDRESS_1200430] will be carried out 
(as needed for WOCBP) (Serum β hCG pregnancy test will be carried out if there is 
a positive urine test)
•alcohol breath test and drug screen (to include at minimum: amphetamines, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651]) 
•Serology (HIV antibody, HBsAg, and hepatitis C virus antibody)]
ALT=alanine aminotransferase ;AST=aspartate aminotransferase ;BUN=blood urea nitrogen ;FSH=follicle -stimulating 
hormone ; [HBsAg=hepatitis B surface antigen]; hCG=human chorionic gonadotropin ; [HIV=human immunodeficiency 
virus]; MCH=mean corpuscular hemoglobin ; MCV=mean corpuscular vol ume;RBC=red blood c ell;SGOT=serum 
glutamic -oxaloacetic transaminase ; SGPT=serum glutamic -pyruvic transaminase ;ULN=upper limit of normal ; 
WBC=white blood cell; WOCBP=women of childbearing potential; WONCBP=women of nonchildbearing potentia l
aFasting : Participants should fast for at least 4 hours prior to glucose measurement.
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08BRCT
PRODUCT:   MK-2060  80
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sig n (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run- in 
intervention) , manufact ured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiol ogical scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent preexisting condition including eith er an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a s uspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
•Any new ca ncer or progression of existing cancer.
08BRCT
PRODUCT:   MK-2060  81
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occu r (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent t o treat a preexisting condition 
that has not worsened.
•Refe r to Section 8.[ADDRESS_1200431] medical occurrence that, at any dose:
Results in death
Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting co ndition that has not 
worsened is not an SAE. )A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
Results in persistent or significant disability/incap acity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomitin g, diarrhea, influenza, 
08BRCT
PRODUCT:   MK-2060  82
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
•In offspring of participant taking the produc t regardless of time to diagnosis.
Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will recor d all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
08BRCT
PRODUCT:   MK-2060  83
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
number, will be blinded on the copi[INVESTIGATOR_180580].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Asses sment of i ntensity /toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity for each AE an d SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort, 
and not interfering with everyday activities (for pe diatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that preve nts normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category used for rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done . This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to ass ess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_4382] 
08BRCT
PRODUCT:   MK-2060  84
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
count, diary, etc), expected pharmacologic effect, or measurement of 
drug/metabolite in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_55530] ’s 
product; (3) the study is a single -dose drug study; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used onl y 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST B E APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC .
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or dru g class 
pharmacology or toxicology?
08BRCT
PRODUCT:   MK-2060  85
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
•The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
•Use the f ollowing scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility of Sponso r’s product relationship:
◦There is evidence of exposure to the Sponsor ’s product . The temporal sequence 
of the AE onset relative to the administration of the Sponsor ’s product is 
reasonable. The AE is more likely explained by [CONTACT_1034] ’s product than by 
[CONTACT_5748].
-No, there is not a re asonable possibility of Sponsor’ s product relationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable 
OR the AE is more likely explained by [CONTACT_26372]’s 
produc t. (Also entered for a participant with overdose without an associated 
AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.
•The causality assessment is 1 of the criteria used when deter mining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in th e CRF.
•The investigator will submit any updated SAE data to the Sponsor within [ADDRESS_1200432]:   MK-2060  86
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponso r via e lectronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper AE Reporting form.
◦Reference Section 8. 5.1for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has bee n taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•Ifthe EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_756] i s acceptable with a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting tim e frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08BRCT
PRODUCT:   MK-2060  87
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
Not applicable.
08BRCT
PRODUCT:   MK-2060  88
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the po stmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_1200433]:   MK-2060  89
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc,d
•IUSc,e
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexu al partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and cor rectly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and th e preferred and usual 
lifestyle of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the prim ary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods) .
aContraceptive use by [CONTACT_93339].
bTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistent ly and correctly).
08BRCT
PRODUCT:   MK-2060  90
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomed ical Research3, 4
The specimens consented and/or collected in this study as outlined in Section 8. 10will be 
used in various experiments to understand:
The biology of how drugs/vaccines work
Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
Other pathways with which drugs/vaccines may interact
The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targe ted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3.Summary of Procedures for Future Biomedical Researc h3, [ADDRESS_1200434]:   MK-2060  91
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical research, thes e will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3, 4
In order t o optimize the resea rch that can be conducted with future biomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
08BRCT
PRODUCT:   MK-2060  92
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200435] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the a nalysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent . 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research3, [ADDRESS_1200436] the Sponsor using the designated mailbox 
(clinical.specimen.management@ MSD .com). Subseque ntly, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be removed 
from the biorepository and destroyed. Documen tation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or destruction, 
if applicable. Any analyses in progr ess at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_93336]. No new analyses would be 
generated after the reques t is received.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens3, [ADDRESS_1200437]:   MK-2060  93
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200438] results are accessible only to the 
authorized Sponsor representatives and the de signated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3, 4
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participa nt include: l ack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and m ake results accessible on a public website in order to
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_88726] .
10. Future Biomedical Research Study Population3, [ADDRESS_1200439] security, policies, and procedures to address participant 
data privacy concerns. D ata privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
08BRCT
PRODUCT:   MK-2060  94
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08BRCT
PRODUCT:   MK-2060  95
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.7 Appendix 7: Country -specific Requirements
Not applicable.
08BRCT
PRODUCT:   MK-2060  96
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.8 Appendix 8:Blood Volume Table
PrestudyTreatment 
Periods PoststudyTotal 
CollectionsmL Per 
CollectionTotal mL/ 
Test
Laboratory Safety Tests 2 9 1 12 12.5 150
HIV/Hepatitis Screen 1 1 5 5
FSH (Females only) [ADDRESS_1200440] 
(Females only)2 1 3 3.5 10.5
Blood (DNA) for genetic analysis 1 1 8.5 8.5
Blood for PT and aPTT at local lab 1 19 1 21 3 63
Blood for plasma ADA and MK-
[ZIP_CODE] 1 5 2.7 13.5
Blood for MK -2060 only 16 16 1.8 28.8
Blood for Clopi[INVESTIGATOR_861175] 3 5 8 4 32
Blood for PT, aPTT, FXI activity by
[CONTACT_35970]16 1 17 8.1 137.7
Total Blood Volume per Male Participanta438.5 mL
Total Blood Volume per Fem ale Participanta452.5 mL
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood ( no more than 
50mLin total ) may be obtained.
08BRCT
PRODUCT:   MK-2060  97
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory values obtained at prestudy (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory values are normal, the participant may enter the study.
B.If a protocol specified laboratory value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study.
C.If ≥1 protocol -specified laboratory value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
a.The participant may be excluded from the study;
b.The participant may be included in the study if the abnormal value(s) is NCS (the 
investigator must annotate the laboratory value “NCS” on the laboratory safety 
test source document).
c.The participant may be included in the study if the abnormality is consistent with 
a pre -existing medical condition which is not excluded per protocol (eg, elevated 
eosinophil count in a participant with asthma or seasonal allergies), the medical
condition should be annotated on the laboratory report .
OR
d.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may 
enter the study.
b.If the repeat test value is still abnormal, the study investigator will 
evaluate the potential participant with a complete history and physical 
examination, looking especially for diseases that could result in the 
abnormal laboratory value in question. If such diseases can be ruled out, 
and if the abnormal laboratory value is not clinically relevant, then the 
participant may enter the study.
D.If there is any clinical uncertainty regarding the significance of an abnormal value, the 
participant will be excluded from the study.
08BRCT
PRODUCT:   MK-2060  98
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
10.10 Appendix 10: Abbreviations
Abbreviation Expanded Term
ADA antidrug antibodies
AE adverse event 
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the curve
AV arteriovenous
bid twice daily
BMI body mass index
BP blood pressure
CCU Cardiac care unit
Cmax maximum plasma concentration
CL clearance
CRF Case Report Form 
CRU clinical research unit
CSR Clinical Study Report
CYP cytochrome P450
DILI drug-induced liver injury
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
EMA European Medicines Agency
ESRD End-stage renal disease
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone 
FXI Factor XI
FXIa Factor XIa
GCP Good Clinical Practice 
GI gastrointestinal
GLP Good Laboratory Practice
GLP -1 Glucagon -like peptide -1
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HD hemodialysis
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB Investigator’s Brochure 
ICF Informed Consent Form
08BRCT
PRODUCT:   MK-2060  99
PROTOCOL/AMENDMENT NO.:   [ADDRESS_1200441]
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
Kt/V Anumber used to quantify hemodialysis .
K –dialyzer clearance of urea
t –dialysis time
V –volume of distribution of urea, approximately equal to patient's total 
body water
mAb monoclonal antibody
NCS not clinically significant
NSAE Nonserious adverse event
NSAID Non-steroidal anti -inflammatory drug
OR objective response
PCL Protocol Clarification Letter
PD pharmacodynamic(s)
PK pharmacokinetic (s)
po orally
PP posterior probability
PT Prothrombin time
QTc Corrected Q -T interval
QW Once weekly
RNA ribonucleic acid
RR respi[INVESTIGATOR_861176](s)
SoA schedule of activities
SOP Standard Operating Procedures
S[LOCATION_003]R suspected unexpected serious adverse reaction
THC Tetrahydrocannabinol
Tmax Time to maximum plasma concentration
t1/[ADDRESS_1200442]:   MK-2060  100
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
Abbreviation Expanded Term
WOCBP woman/women of childbearing potential
WONCBP woman/women of nonchildbearing potential
08BRCT
PRODUCT:   MK-2060  101
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
11 REFERENCES
[Asakai, R., et al 1991] Asakai R, Chung DW, Davie EW, Seligsohn U. 
Factor XI deficiency in Ashkenazi Jews in Israel. 
N Engl J Med. 1991 Jul 18;325(3):153- 8.[050RJ8]
[Bethune, C., et al 
2017]Bethune C, Walsh M, Jung B, Yu R, Geary RS, 
Bhanot S. Pharmacokinetics and 
pharmacodynamics of Ionis -FXI(RX), an 
antisense inhibitor of factor XI, in patients with 
end-stage renal disease on hemodialysis. Blood. 
2017;130:1116.[0559X2]
[Breslin, W. J., et al 
2014]Breslin WJ, Hilbish KG, Page TJ, C outant DE. 
Assessment of fetal exposure risk following 
seminal excretion of a therapeutic IgG4 (T -IgG4) 
monoclonal antibody using a rabbit model. 
Reprod Toxicol. 2014;48:124 -31.[07W827]
[Buller, H. R., et al 
2015]Buller HR, Bethune C, Bhanot S, Gailani D, 
Monia BP, Raskob GE, et al. Factor XI antisense 
oligonucleotide for prevention of venous 
thrombosis. N Engl J Med. 2015 Jan 
15;372(3):232- 40.[04T0MV]
[Ellsworth K 2018] pd002mk2060 -MK-2060: Assessment of 
Human Plasma Coagulation by [CONTACT_861194], 27 -Sep-2018.[0522VM]
[Kaufman, J. S., et al 
2000]Kaufman JS, Fiore L, Hasbargen JA, O'Connor 
TZ, Perdriset G. A pharmacodynamic study of 
clopi[INVESTIGATOR_861177]. J 
Thromb Thrombolysis. 2000;10:127 -31.[07W3GX]
[Moffat, G. J., et al 
2014]Moffat GJ, Retter MW, Kwon G, Loomis M, 
Hock MB, Hall C, et al. Placental transfer of a 
fully human IgG2 monoclonal antibody in the 
cynomolgus monkey, rat, and rabbit: a 
comparative assessment from during 
organogenesis to late gestation. Birth Defects Res 
B Dev Reprod Toxicol. 2014;101:178 -88.[07W82F]
08BRCT
PRODUCT:   MK-2060  102
PROTOCOL/AMENDMENT NO.:   008 -01  
MK-2060 -008-01FINAL PROTOCOL 09-JUN-2022
[Perek, S., et al 2017] Perek S, Kotler A, Cohen S, Rennert G, Stein N, 
Saliba W, et al. Risk for major bleeding in 
patients with severe factor XI deficienc y treated 
with aspi[INVESTIGATOR_8258] [abstract]. Blood. 
2017 Dec 7;130(suppl 1):3670.[07W3GW]
[Sohn, W., et al 2015] Sohn W, Lee E, Kankam MK, Egbuna O, Moffat 
G, Bussiere J, et al. An open -label study in 
healthy men to evaluate the risk of seminal flu id 
transmission of denosumab to pregnant partners. 
Br J Clin Pharmacol. 2015;81(2):362 -9.[07W82C]
08BRCT